

Copper-Mediated Direct Alkoxylation of Arenes Using an N,O-Bidentate Directing System


Lin-Bao Zhang,[†] Xin-Qi Hao,[†] Shou-Kun Zhang,[†] Ke Liu,[†] Baozeng Ren,[‡] Jun-Fang Gong,[†] Jun-Long Niu,^{*,†} and Mao-Ping Song^{*,†}

[†]The College of Chemistry and Molecular Engineering, Henan Key Laboratory of Chemical Biology and Organic Chemistry, Zhengzhou University, Zhengzhou 450001, People's Republic of China

[‡]School of Chemical Engineering and Energy, Zhengzhou University, Zhengzhou 450001, People's Republic of China

Supporting Information

ABSTRACT: Highly effective CuCl-mediated C—H alkoxylation of arenes and heteroarenes has been developed by using a 2-aminopyridine 1-oxide moiety as an N,O-bidentate directing group. The reaction proceeds smoothly using a broad range of substrates to afford *o*-alkoxylated benzoic and heteroaromatic amide products. Moreover, the reaction system shows remarkable compatibility when hexafluoroisopropanol is used as a coupling partner; halogen, nitro, ether, alkoxy, ester, and sulfonyl functional groups are all tolerated. The directing group can be easily removed by base hydrolysis, affording *o*-alkoxylated benzoic acids.



INTRODUCTION

Diverse C—H bond functionalization methodologies have been developed in the past two decades.¹ Compared to traditional methods, direct C—H functionalization offers more efficient ways of constructing complex chemical frameworks without prefunctionalization of the starting materials. Recently, tremendous C—C,² C—N,³ and C—O⁴ bond-forming reactions have proven the practical utility and feasibility of direct functionalization protocols. However, most examples of direct functionalization of C—H bonds have been performed by applying expensive metal catalysts such as palladium,⁵ rhodium,⁶ or ruthenium.⁷ On the other hand, copper salts are abundant and inexpensive alternatives to the rare metals described above and have been reported in Cu-catalyzed or Cu-mediated cross-dehydrogenative coupling reactions by Miura⁸ and other groups⁹ recently.

Aryl ethers are common structural motifs in many natural products, pharmaceuticals, and functional materials.¹⁰ From a synthetic perspective, dehydrogenative cross coupling between arenes and alcohols compares favorably with classical methods such as Pd-catalyzed Buchwald–Hartung couplings,¹¹ and Cu-catalyzed Ullmann,¹² Chan–Evans–Lam,¹³ Williamson,¹⁴ and Mitsunobu¹⁵ reactions. Considering the fact that fruitful strategies for direct hydroxylations,¹⁶ acetoxylations,¹⁷ and even phenoxylations^{4a–d} have been developed, the alkoxylation of arenes remains a challenging topic because alkanols are easily oxidized to their corresponding aldehydes, ketones, or carboxylic acids.¹⁸ In general, palladium salt is a highly active catalyst for this type of transformation.¹⁹ Recently, pioneering copper-catalyzed dehydrogenative alkoxylation of arenes has been reported by Gooßen.²⁰ Moreover, Stahl and co-workers²¹ have observed the etherification of a macrocyclic copper ligand on the addition of alkanols and have performed a fundamental

mechanistic study on Cu(II)-mediated methoxylation of 8-aminoquinoline benzamide using 2 equiv of Cu(OAc)₂.

In 2005, Daugulis and co-workers employed picolinamide and 8-aminoquinoline as *N,N*-bidentate directing groups for palladium-catalyzed C—H bond functionalization.²² Recently, methods for chelating-assisted C—H bond functionalization by employing a bidentate directing group have been developed by the groups of Daugulis,²³ Miura,^{8b,c} Nakamura,²⁴ Chatani,²⁵ Chen,²⁶ and others.²⁷ The noteworthy advantage of these transformations is that abundant, relatively cheap first-row transition metals, including copper, iron, and nickel, are used.²⁸ Moreover, our laboratory was the first to report the 2-aminopyridine 1-oxide moiety as an N,O-bidentate directing group for selective mono- or diaryloxylation of benzamides by applying a stoichiometric copper acetate.²⁹ Encouraged by the notable progress in C—H bond functionalization methodologies mentioned above, we studied the alkoxylation of C—H bonds as a complementary alternative for the synthesis of *o*-alkoxylated benzoic acids.

RESULTS AND DISCUSSION

We first investigated the reaction of 2-benzamidopyridine 1-oxide (**1a**) with ethanol (**2a**). The results are summarized in Table 1.

When **1a** was treated with stoichiometric Cu(OAc)₂ in ethanol (**2a**) at 130 °C, desired ethoxylated product **3aa** was obtained in 21% yield (entry 1). As we had previously observed a beneficial effect of base composition on the aryloxylation of benzamide substrates,²⁹ we next tested various bases (entries 2–9). Among them, K₂CO₃ proved to be effective and led to an increase in the yield to 49% (entry 9). Subsequently, a series of

Received: August 31, 2014



Table 1. Optimization of Reaction Conditions^a

| entry | Cu salt | base | additive ^b | solvent ^b | yield (%) ^c |
|-----------------|----------------------|--------------------------|------------------------|----------------------|------------------------|
| 1 | Cu(OAc)_2 | | | EtOH | 21 |
| 2 | Cu(OAc)_2 | KO- <i>t</i> Bu | | EtOH | 38 |
| 3 | Cu(OAc)_2 | NaOEt | | EtOH | 33 |
| 4 | Cu(OAc)_2 | KOH | | EtOH | 25 |
| 5 | Cu(OAc)_2 | DBU | | EtOH | 20 |
| 6 | Cu(OAc)_2 | TMG | | EtOH | 36 |
| 7 | Cu(OAc)_2 | Cs_2CO_3 | | EtOH | 44 |
| 8 | Cu(OAc)_2 | Na_2CO_3 | | EtOH | 45 |
| 9 | Cu(OAc)_2 | K_2CO_3 | | EtOH | 49 |
| 10 | Cu(acac)_2 | K_2CO_3 | | EtOH | trace |
| 11 | CuBr_2 | K_2CO_3 | | EtOH | trace |
| 12 | CuCl_2 | K_2CO_3 | | EtOH | 22 |
| 13 | $\text{Cu(ClO}_4)_2$ | K_2CO_3 | | EtOH | nr |
| 14 | Cu(OTf)_2 | K_2CO_3 | | EtOH | nr |
| 15 | CuF_2 | K_2CO_3 | | EtOH | 57 |
| 16 | CuI | K_2CO_3 | | EtOH | 53 |
| 17 | CuCl | K_2CO_3 | | EtOH | 61 |
| 18 | CuCl | DMAP | | EtOH | 49 |
| 19 | CuCl | bpy | | EtOH | 51 |
| 20 | CuCl | TMEDA | | EtOH | 54 |
| 21 | CuCl | Py | | EtOH | 77 |
| 22 | CuCl | EtOH/Py (1:1) | | | 84 |
| 23 ^d | CuCl | K_2CO_3 | EtOH/Py (1:1) | | 66 |
| 24 ^e | CuCl | K_2CO_3 | EtOH/Py (1:1) | | 60 |
| 25 | | K_2CO_3 | EtOH/Py (1:1) | | nr |
| 26 ^f | CuCl | K_2CO_3 | EtOH/Py (1:1) | | trace |

^aReaction conditions: [Cu] (0.2 mmol), additive (0.2 mmol), base (0.1 mmol), **1a** (0.2 mmol), solvent (1.5 mL), air atmosphere, 130 °C, 12 h, unless otherwise noted. ^bPy = pyridine. ^cIsolated yields; nr = no reaction. ^dCuCl (0.1 mmol). ^eRun at 110 °C. ^fUnder argon atmosphere.

copper salts were investigated in the reaction, including Cu(acac)_2 (acac = acetylacetone), CuBr_2 , CuCl_2 , $\text{Cu}(\text{ClO}_4)_2$, Cu(OTf)_2 , CuF_2 , CuI , and CuCl (entries 10–17, respectively). The use of CuCl resulted in a significant increase in yield (entry 17). The addition of N donor ligands to stabilize the copper salts resulted in slightly decreased yields (entries 18–20). However, the use of pyridine as an additive substantially influenced the yields to give a superior result (entry 21), similar to the observation of Daugulis in copper-catalyzed fluorination reactions.^{23a} When pyridine was used as a cosolvent, and the ratio of pyridine to ethanol was changed to 1:1 (v/v), the yield increased to 84% (entry 22). Unfortunately, decreasing the amount of CuCl or lowering the reaction temperature reduced the yields (entries 23 and 24). Control experiments revealed that no reaction took place without copper salts and that air atmosphere was crucial (entries 25 and 26). Furthermore, the 2-aminopyridine 1-oxide motif appeared to be more effective under the current identical conditions compared to other bidentate coordinating groups (Figure 1A–C). Noteworthily, 8-aminoquinoline benzamide **A** was inefficient during the dehydrogenative ethoxylation process (yield <5%) regardless of the optimized reaction conditions that Daugulis employed for





Figure 1. Varieties of directing groups.


copper-catalyzed alkoxylation.^{23d} Structurally similar monodentate directing groups (Figure 1D–F) failed to promote this reaction either, indicating that the *N,O*-bidentate coordinating group is essential for transformation.

With the optimized reaction conditions for ethoxylation in hand, we tested the reactions of a series of 2-benzamidopyridine 1-oxide derivatives bearing different functional groups with ethanol. The results are listed in Scheme 1. A wide range of aryl

Scheme 1. Reaction Scope with Respect to Amides^a

^aReaction conditions: CuCl (0.20 mmol), amide (0.20 mmol), K_2CO_3 (0.1 mmol), EtOH (0.75 mL), pyridine (0.75 mL), at 130 °C, under air, for 12 h. Isolated yield.

substrates bearing electron-withdrawing or -donating groups underwent monoethoxylation smoothly to afford their corresponding products (**3ba**–**3la**) in 50–87% yields. Diethoxylated products were not observed in all cases. The *o*-substituted substrates, such as *o*-methylbenzamide **1q** and *o*-chlorobenzamide **1r**, did not work. Furthermore, 2-benzamidopyridine 1-oxide derivatives possessing electron-donating functional groups in the *p*-position gave good yields (**3ba**, **3ca**, and **3la**). Electron-withdrawing functional groups such as chloro (**1g**), bromo (**1h**), and iodo (**1i**) also provided the desired products (**3ga**–**3ia**), albeit in moderate yields. Significantly, the

Scheme 2. Reaction Scope with Respect to Alcohols^a

^aReaction conditions: CuCl (0.20 mmol), **1a** (0.20 mmol), K₂CO₃ (0.1 mmol), alcohols (0.75 mL), pyridine (0.75 mL), at 130 °C, under air, for 12 h. ^bPyridine solvent. Alcohols (2 mmol). ^cThe configuration is determined on a Daicel Chiraldpak AD-H column with hexane/2-propanol (90:10). Flow rate = 0.1 mL/min, UV wavelength = 254 nm, and retention time = 6.0 min (one signal).


halo-substituted benzamide moiety remained intact. Strong electron-withdrawing functional groups, such as NO₂, inhibited the reaction and could not yield the target product under the optimized reaction conditions. These results add to the growing evidence that the electron density of substrates plays a more important role than steric hindrance factors. For *m*-substituted substrates (**1d**, **1e**, and **1k**), selective ethoxylation occurred at the less-hindered position to give a good yield and excellent regioselectivity.

We next explored a variety of alcohols in copper-mediated, direct alkoxylation of **1a** (Scheme 2) and found that the strategy of direct dehydrogenative alkoxylation coupling has broad applications. Both primary and secondary alcohols could proceed smoothly, affording their corresponding alkoxylated products in moderate to good yields (**3ab**–**3ah**). The reaction system tolerated a range of functional groups, such as heteroaromatic (**2c**), branched (**2d**), and olefin (**2e**) alcohols. The chiral alcohol menthol (**2i**) could react while retaining its configuration. The benzylic alcohols did not give the desired products because they were easily oxidized at high temperature.³⁰ Long-chain alcohols (**2j** and **2k**) also provided the corresponding ethers **3aj** and **3ak** in moderate yields when pyridine was used as the solvent. To our surprise, hexafluoroisopropanol (HFIP) also underwent alkoxylation to give monoalkoxylated product **3al** and dialkoxylated product **3'al** in a 2.8:1 ratio and 93% combined yield.

In light of the extraordinary potential for fluorine-containing molecules in medicinal chemistry and chemical biology,³¹ we

examined the use of HFIP as the coupling partner (Scheme 3). When changing the ratio of pyridine and HFIP to 1:4 (v/v), we found that a variety of aryl amide substrates **1** with electron-withdrawing or -donating groups were hexafluoroisopropoxylated to give good to excellent yields. Doubly alkoxylated products **3'** were detected for substrates that bear functional groups at the para position of the aromatic ring (**3il** and **3ll**–**3ol**). Similar to ethoxylation, excellent regioselectivity was obtained for *m*-substituted substrates, and alkoxylation only occurred at the less-congested site (**3el**, **3kl**, and **3ul**–**3wl**). For *o*-substituted substrates, single monoalkoxylated products (**3ql**–**3tl**) were isolated with 54–93% yields. It is worth noting that substrate **1s**, which bears the strong electron-withdrawing NO₂ functional group, also underwent alkoxylation smoothly and transformed into its corresponding product in a synthetically useful yield (**3sl**). The naphthyl substrate (**1x**) could be successfully reacted with HFIP with regioselectively at the 2-position in 81% yield. We were pleased to find that heteroaryl substrates (**1o**, **1y**, and **1z**) proceeded smoothly to give their corresponding products in good yields (75, 74, and 38%, respectively).

To obtain more insight into the mechanism, some controlled experiments were performed. The addition of 2,2,6,6-tetramethylpiperidine-N-oxyl (TEMPO) as a radical quencher completely inhibited the reaction (Scheme 4, eq 1), suggesting that the reaction involved a radical pathway. TEMPOH rather



Scheme 3. Exceptional Compatibility with HFIP^a

^aReaction conditions: CuCl (0.20 mmol), **1** (0.20 mmol), K₂CO₃ (0.1 mmol), pyridine (0.3 mL), HFIP (1.2 mL). ^bThe combined isolated yield of **3** and **3'** is given. The ratio of **3**/**3'** is in parentheses and is determined by ¹H NMR analysis of the crude reaction mixture; **3** and **3'** were separated by silica gel column chromatography.


than TEMPOEt was detected by LC-MS, which is in agreement with findings by Stahl and co-workers.^{18a} Next, treatment of a 1:1 mixture of [D₅]-**1a** and **1a** with ethanol resulted in a kinetic isotope effect (KIE) of 2.5 (Scheme 4, eq 2). This finding indicated that the C—H activation of the arene is rate limiting. The single-electron-transfer (SET) mechanism proposed by Yu in copper-mediated chlorination reactions, in which a low kinetic isotope effect had been found, could be ruled out.^{4a} A hydroxyarene intermediate resulting from an attack of H₂O on the benzamide was excluded based on the fact that 2-(2-hydroxybenzamido)pyridine 1-oxide (**1A**)

was not transformed into **3aa** under the standard reaction conditions (Scheme 4, eq 3). Moreover, 2-(thiophen-2-yl)-acetaldehyde **4** was obtained from 2-thiopheneethanol under the reaction conditions in the absence of substrate **1a**, which can be used as indirect evidence of alkoxy radical formation (Scheme 4, eq 4). However, when TEMPO was added to the reaction mixture under the optimized conditions using HFIP as the coupling partner, it did not inhibit the reaction. Moreover, treatment of a 1:1 mixture of [D₅]-**1a** and **1a** with HFIP provided a KIE of 2.1. HFIP (*pK_a* = 9.3) is more acidic, which differs from ethanol (*pK_a* = 15.9), and is actually more similar

Scheme 4. Controlled Experiments

Figure 2. Plausible mechanism for *o*-alkylation.

Scheme 5. Removal of the Directing Group



to phenol ($pK_a = 9.9$). It seems that the reaction proceeds via a CNO-pincer Cu(III) intermediate, which we have clarified in the arylation of benzamides.²⁹

On the basis of these investigations, we searched the literature^{8b,20b,21} and developed a plausible reaction mechanism (Figure 2). First, CuCl is oxidized via the formation of Cu(II)-superoxide species 5,³² which could be easily reduced to produce hydroperoxo form 7 after protonation while alkoxy radical 6 is simultaneously formed in the process.³³ Then, ligand exchange with 1a occurs to form *N*,*O*-chelated complex 8. The alkoxy radical is transferred to Cu(II) species 8 to give Cu(III)

complex 9. Finally, intermediate 9 furnishes desired product 3aa by reductive elimination.

The 2-aminopyridine 1-oxide directing group can be easily removed by base hydrolysis. For example, treatment of 3aa with NaOH in EtOH at 80 °C for 8 h affords 2-ethoxybenzoic acid 10 in high yield (Scheme 5).

CONCLUSIONS

In summary, we have developed a copper-mediated coupling of benzamides and alcohols with the aid of an *N*,*O*-bidentate directing group derived from 2-aminopyridine 1-oxide. This new-fashioned strategy is operationally simple and possesses a broad substrate scope, thus providing a convenient synthetic route to *o*-alkylated benzoic and heteroaromatic acids. Moreover, the exceptional compatibility of the alkylation reaction with HFIP renders this reaction highly valuable for the synthesis of medicinal fluorine-containing compounds. Further exploration extending this strategy to sp^3 C—H groups of aliphatic substrates through a detailed mechanistic study is currently in progress.

EXPERIMENTAL SECTION

General. Unless otherwise noted, all solvents and reagents were purchased commercially and used directly. ¹H NMR, ¹³C NMR, and ¹⁹F NMR spectra were recorded at 400, 100, and 376 MHz, respectively, using tetramethylsilane as an internal standard. Chemical shift multiplicities are represented as follows: s = singlet, d = doublet, t = triplet, q = quartet, p = pentalet, m = multiplet, dd = doublet, bs = broad singlet. HRMS spectra were obtained on a Q-TOF mass spectrometer using the ESI technique.

Amide substrates **1a–1z** were prepared according to published procedures.²⁹

2-(*tert*-Butyl)benzamido)pyridine 1-Oxide (1c**).** Purified by column chromatography on silica gel with CH₂Cl₂/acetone (5:1) as an eluent (*R*_f = 0.37) to afford a white solid (1.20 g, 74%, mp 123–124 °C from 1:3 hexane/dichloromethane). ¹H NMR (400 MHz, CDCl₃): δ 10.91 (s, 1H), 8.63 (dd, *J* = 8.5, 1.7 Hz, 1H), 8.32 (dd, *J* = 6.5, 1.1 Hz, 1H), 7.97–7.94 (m, 2H), 7.56–7.53 (m, 2H), 7.42–7.38 (m, 1H), 7.04–7.00 (m, 1H), 1.36 (s, 9H). ¹³C NMR (100 MHz, CDCl₃): δ 167.3, 160.5, 159.7, 137.5, 129.4, 128.1, 118.6, 117.3, 115.5, 115.0, 35.2, 30.9. HRMS (positive ESI): calcd for C₁₆H₁₉N₂O₂ [M + H], 271.1447; found, 271.1442.

2-(Bromobenzamido)pyridine 1-Oxide (1h**).** Purified by column chromatography on silica gel with CH₂Cl₂/acetone (5:1) as an eluent (*R*_f = 0.37) to afford a white solid (1.32 g, 75%, mp 188–189 °C from 1:3 hexane/dichloromethane). ¹H NMR (400 MHz, CDCl₃): δ 10.92 (s, 1H), 8.58 (dd, *J* = 8.5, 1.7 Hz, 1H), 8.30 (dd, *J* = 6.5, 1.0 Hz, 1H), 7.90–7.88 (m, 2H), 7.74–7.71 (m, 2H), 7.42–7.38 (m, 1H), 7.07–7.03 (m, 1H). ¹³C NMR (100 MHz, CDCl₃): δ 164.5, 144.4, 137.2, 132.4, 132.0, 129.3, 128.6, 128.1, 119.0, 115.0. HRMS (positive ESI): calcd for C₁₂H₁₀BrN₂O₂ [M + H], 292.9926; found, 292.9919.

2-(4-Iodobenzamido)pyridine 1-Oxide (1i**).** Purified by column chromatography on silica gel with CH₂Cl₂/acetone (5:1) as an eluent (*R*_f = 0.39) to afford a white solid (1.55 g, 76%, mp 198–199 °C from 1:3 hexane/dichloromethane). ¹H NMR (400 MHz, CDCl₃): δ 10.92 (s, 1H), 8.58 (dd, *J* = 8.5, 1.6 Hz, 1H), 8.30 (dd, *J* = 6.5, 1.0 Hz, 1H), 7.89–7.85 (m, 2H), 7.68–7.65 (m, 2H), 7.42–7.38 (m, 1H), 7.06–7.02 (m, 1H). ¹³C NMR (100 MHz, CDCl₃): δ 164.6, 144.3, 138.2, 137.1, 132.5, 129.1, 128.3, 118.9, 114.8, 100.5. HRMS (positive ESI): calcd for C₁₂H₁₀IN₂O₂ [M + H], 340.9787; found, 340.9781.

2-(4-Methoxycarbonyl)benzamido)pyridine 1-Oxide (1n**).** Purified by column chromatography on silica gel with CH₂Cl₂/acetone (5:1) as an eluent (*R*_f = 0.44) to afford a white solid (1.22 g, 75%, mp 131–132 °C from 1:3 hexane/dichloromethane). ¹H NMR (400 MHz, CDCl₃): δ 10.99 (s, 1H), 8.61 (dd, *J* = 8.5, 1.7 Hz, 1H), 8.32 (dd, *J* = 6.5, 1.0 Hz, 1H), 8.21–8.19 (m, 2H), 8.09–8.06 (m, 2H), 7.45–7.40 (m, 1H), 7.09–7.05 (m, 1H), 3.97 (s, 3H). ¹³C NMR (100 MHz, CDCl₃): δ 166.0, 164.4, 144.3, 137.1, 136.8, 134.0, 130.2, 128.4, 127.7, 119.1, 114.9, 52.6. HRMS (positive ESI): calcd for C₁₄H₁₃N₂O₄ [M + H], 273.0875; found, 273.0871.

2-(2-Chlorobenzamido)pyridine 1-Oxide (1r**).** Purified by column chromatography on silica gel with CH₂Cl₂/acetone (5:1) as an eluent (*R*_f = 0.38) to afford a white solid (1.07 g, 72%, mp 151–152 °C from 1:3 hexane/dichloromethane). ¹H NMR (400 MHz, CDCl₃): δ 10.82 (s, 1H), 8.63 (dd, *J* = 8.4, 1.7 Hz, 1H), 8.30 (dd, *J* = 6.5, 1.0 Hz, 1H), 7.79 (dd, *J* = 7.6, 1.4 Hz, 1H), 7.52–7.45 (m, 2H), 7.44–7.38 (m, 2H), 7.08–7.04 (m, 1H). ¹³C NMR (100 MHz, CDCl₃): δ 164.7, 144.2, 137.3, 133.7, 132.5, 131.4, 130.8, 130.3, 128.3, 127.3, 119.2, 115.2. HRMS (positive ESI): calcd for C₁₂H₁₀ClN₂O₂ [M + H], 249.0431; found, 249.0426.

2-(2-Nitrobenzamido)pyridine 1-Oxide (1s**).** Purified by column chromatography on silica gel with CH₂Cl₂/acetone (4:1) as an eluent (*R*_f = 0.30) to afford a yellow solid (780 mg, 51%, mp 203–204 °C from 1:3 hexane/dichloromethane). ¹H NMR (400 MHz, CDCl₃): δ 10.50 (s, 1H), 8.54 (dd, *J* = 8.4, 1.2 Hz, 1H), 8.19 (d, *J* = 5.8 Hz, 1H), 8.13 (d, *J* = 7.9 Hz, 1H), 7.76–7.72 (m, 1H), 7.67–7.64 (m, 2H), 7.42–7.38 (m, 1H), 7.07–7.03 (m, 1H). ¹³C NMR (100 MHz, CDCl₃): δ 164.6, 146.4, 143.9, 137.2, 134.0, 131.6, 131.5, 128.5, 128.3, 124.8, 119.5, 115.3. HRMS (positive ESI): calcd for C₁₂H₁₀N₃O₄ [M + H], 260.0671; found, 260.0667.

2-(Thiophene-2-carboxamido)pyridine 1-Oxide (1y**).** Purified by column chromatography on silica gel with CH₂Cl₂/acetone (4:1) as an eluent (*R*_f = 0.35) to afford a white solid (924 mg, 70%, mp 142–143 °C from 1:3 hexane/dichloromethane). ¹H NMR (400 MHz, CDCl₃): δ 10.90 (s, 1H), 8.55 (d, *J* = 8.4 Hz, 1H), 8.30 (d, *J* = 6.5 Hz, 1H), 7.62–7.61 (m, 1H), 7.40–7.36 (m, 1H), 7.34–7.33 (m, 1H), 7.05–7.01 (m, 1H), 6.61–6.60 (m, 1H). ¹³C NMR (100 MHz, CDCl₃): δ 159.0, 146.9, 145.7, 144.1, 137.3, 128.1, 118.9, 117.0, 114.9, 112.9. HRMS (positive ESI): calcd for C₁₀H₉N₂O₂S [M + H], 221.0385; found, 221.0379.

2-(Furan-2-carboxamido)pyridine 1-Oxide (1z**).** Purified by column chromatography on silica gel with CH₂Cl₂/acetone (4:1) as an eluent (*R*_f = 0.40) to afford a white solid (881 mg, 72%, mp 137–138 °C from 1:3 hexane/dichloromethane). ¹H NMR (400 MHz, CDCl₃): δ 10.79 (s, 1H), 8.53 (dd, *J* = 8.5, 1.7 Hz, 1H), 8.30 (dd, *J* = 6.5, 1.1 Hz, 1H), 7.80 (dd, *J* = 3.8, 1.0 Hz, 1H), 7.66 (dd, *J* = 5.0, 1.0 Hz, 1H), 7.41–7.37 (m, 1H), 7.19–7.17 (m, 1H), 7.05–7.01 (m, 1H). ¹³C NMR (100 MHz, CDCl₃): δ 159.8, 144.2, 138.0, 137.0, 132.7, 130.1, 128.3, 128.2, 118.6, 114.7. HRMS (positive ESI): calcd for C₁₀H₉N₂O₃ [M + H], 205.0613; found, 205.0608.

Typical Procedure for Copper-Mediated Dehydrogenative Alkoxylation Coupling. A screw cap vial was equipped with a magnetic stir bar and charged with benzamide substrate **1** (0.2 mmol), CuCl (19.8 mg, 0.2 mmol), freshly distilled anhydrous alcohol (0.75 mL), and freshly distilled pyridine (0.75 mL). The resulting mixture was stirred at 35 °C for 30 min followed by the addition of K₂CO₃ (13.8 mg, 0.1 mmol) and stirring for an additional 5 min at 35 °C. Then, the suspension was kept stirring for 12 h at 130 °C. The resulting crude mixture was allowed to cool to room temperature and quenched with 2 M HCl aqueous solution (5 mL). The mixture was extracted with ethyl acetate (3 × 15 mL). The combined organic layers were dried over anhydrous MgSO₄, filtered, and concentrated in a vacuum. The resulting residue was purified by column chromatography with eluent to give corresponding alkyl-aryl ether **3**.

2-(2-Ethoxybenzamido)pyridine 1-Oxide (3aa**).** Purified by analytical TLC on silica gel with CH₂Cl₂/acetone (6:1) as an eluent (*R*_f = 0.35) to afford a white solid (43 mg, 84%, mp 140–141 °C from 1:5 hexane/dichloromethane). ¹H NMR (400 MHz, CDCl₃): δ 12.30 (s, 1H), 8.74 (dd, *J* = 8.5, 1.8 Hz, 1H), 8.31–8.28 (m, 2H), 7.55–7.51 (m, 1H), 7.38–7.34 (m, 1H), 7.13–7.09 (m, 1H), 7.07 (d, *J* = 8.4 Hz, 1H), 7.02–6.98 (m, 1H), 4.35 (q, *J* = 7.0 Hz, 2H), 1.72 (t, *J* = 7.0 Hz, 3H). ¹³C NMR (100 MHz, CDCl₃): δ 164.0, 157.5, 145.4, 137.4, 134.3, 132.7, 127.8, 121.1, 120.5, 118.5, 115.9, 112.4, 65.4, 14.8. HRMS (positive ESI): calcd for C₁₄H₁₅N₂O₃ [M + H], 259.1083; found, 259.1081.

2-(4-Methyl-2-ethoxybenzamido)pyridine 1-Oxide (3ba**).** Purified by analytical TLC on silica gel with CH₂Cl₂/acetone (3:1) as an eluent (*R*_f = 0.32) to afford a white solid (46 mg, 85%, mp 162–163 °C from 1:5 hexane/dichloromethane). ¹H NMR (400 MHz, CDCl₃): δ 12.16 (s, 1H), 8.66 (d, *J* = 8.4 Hz, 1H), 8.20–8.18 (m, 1H), 8.09–8.07 (d, *J* = 8.0 Hz, 1H), 7.26–7.23 (m, 1H), 6.91–6.88 (m, 1H), 6.83 (d, *J* = 8.0 Hz, 1H), 6.77 (s, 1H), 4.24 (q, *J* = 7.0 Hz, 2H), 2.32 (s, 3H), 1.63 (t, *J* = 7.0 Hz, 3H). ¹³C NMR (100 MHz, CDCl₃): δ 164.0, 157.4, 145.5, 137.4, 132.5, 127.9, 122.0, 118.3, 117.8, 115.7, 113.0, 65.2, 21.9, 14.8. HRMS (positive ESI): calcd for C₁₅H₁₇N₂O₃ [M + H], 273.1239; found, 273.1234.

2-(4-*tert*-Butyl-2-ethoxybenzamido)pyridine 1-Oxide (3ca**).** Purified by analytical TLC on silica gel with CH₂Cl₂/acetone (3:1) as an eluent (*R*_f = 0.42) to afford a white solid (52 mg, 83%, mp 127–128 °C from 1:5 hexane/dichloromethane). ¹H NMR (400 MHz, CDCl₃): δ 12.27 (s, 1H), 8.75 (dd, *J* = 8.5, 1.7 Hz, 1H), 8.29 (dd, *J* = 6.5, 1.0 Hz, 1H), 8.20 (d, *J* = 8.3 Hz, 1H), 7.37–7.33 (m, 1H), 7.14 (dd, *J* = 8.4, 1.7 Hz, 1H), 7.05 (d, *J* = 1.6 Hz, 1H), 7.00–6.96 (m, 1H), 4.37 (q, *J* = 7.0 Hz, 2H), 1.73 (t, *J* = 7.0 Hz, 3H), 1.36 (s, 9H). ¹³C NMR (100 MHz, CDCl₃): δ 164.0, 158.6, 157.3, 145.5, 137.3, 132.3, 127.8, 118.4, 118.3, 117.8, 115.8, 109.4, 65.1, 35.4, 31.1, 14.8. HRMS (positive ESI): calcd for C₁₈H₂₃N₂O₃ [M + H], 315.1709; found, 315.1705.

2-(5-Methoxy-2-ethoxybenzamido)pyridine 1-Oxide (3da**).** Purified by analytical TLC on silica gel with CH₂Cl₂/acetone (3:1) as an eluent (*R*_f = 0.31) to afford a white solid (35 mg, 61%, mp 179–180 °C

from 1:5 hexane/dichloromethane). ^1H NMR (400 MHz, CDCl_3): δ 12.40 (s, 1H), 8.73 (dd, $J = 8.5, 1.7$ Hz, 1H), 8.30–8.29 (m, 1H), 7.81 (d, $J = 3.2$ Hz, 1H), 7.38–7.34 (m, 1H), 7.11–7.08 (m, 1H), 7.02–7.00 (m, 2H), 4.31 (q, $J = 7.0$ Hz, 2H), 3.85 (s, 3H), 1.69 (t, $J = 7.0$ Hz, 3H). ^{13}C NMR (100 MHz, CDCl_3): δ 163.8, 153.6, 151.9, 145.4, 137.4, 127.8, 121.3, 120.8, 118.6, 115.8, 115.4, 114.0, 65.8, 55.9, 14.8. HRMS (positive ESI): calcd for $\text{C}_{15}\text{H}_{17}\text{N}_2\text{O}_4$ [M + H], 289.1188; found, 289.1185.

2-(5-Methyl-2-ethoxybenzamido)pyridine 1-Oxide (3ea).

Purified by analytical TLC on silica gel with $\text{CH}_2\text{Cl}_2/\text{acetone}$ (3:1) as an eluent ($R_f = 0.33$) to afford a white solid (35 mg, 64%, mp 191–192 °C from 1:5 hexane/dichloromethane). ^1H NMR (400 MHz, CDCl_3): δ 12.32 (s, 1H), 8.74 (dd, $J = 8.5, 1.8$ Hz, 1H), 8.30–8.28 (m, 1H), 8.08 (d, $J = 2.2$ Hz, 1H), 7.38–7.31 (m, 2H), 7.01–6.97 (m, 1H), 6.96 (d, $J = 8.6$ Hz, 1H), 4.31 (q, $J = 7.0$ Hz, 2H), 2.36 (s, 3H), 1.70 (t, $J = 7.0$ Hz, 3H). ^{13}C NMR (100 MHz, CDCl_3): δ 164.2, 155.5, 145.5, 137.3, 134.9, 132.7, 130.4, 127.8, 120.0, 118.4, 115.9, 112.4, 65.3, 20.4, 14.8. HRMS (positive ESI): calcd for $\text{C}_{15}\text{H}_{17}\text{N}_2\text{O}_3$ [M + H], 273.1239; found, 273.1236.

2-(3-Ethoxy-[1,1'-biphenyl]-4-ylcarboxamido)pyridine 1-Oxide (3fa). Purified by analytical TLC on silica gel with $\text{CH}_2\text{Cl}_2/\text{acetone}$ (3:1) as an eluent ($R_f = 0.36$) to afford a white solid (39 mg, 59%, mp 174–175 °C from 1:3 hexane/dichloromethane). ^1H NMR (400 MHz, CDCl_3): δ 12.32 (s, 1H), 8.76 (dd, $J = 8.6, 1.7$ Hz, 1H), 8.34 (d, $J = 8.2$ Hz, 1H), 8.31–8.29 (m, 1H), 7.64–7.62 (m, 2H), 7.50–7.46 (m, 2H), 7.43–7.41 (m, 1H), 7.36–7.32 (m, 2H), 7.25–7.24 (m, 1H), 7.02–6.98 (m, 1H), 4.43 (q, $J = 7.0$ Hz, 2H), 1.75 (t, $J = 7.0$ Hz, 3H). ^{13}C NMR (100 MHz, CDCl_3): δ 163.8, 157.7, 147.4, 145.4, 139.9, 137.3, 133.2, 129.0, 128.4, 127.9, 127.3, 119.9, 119.2, 118.5, 115.9, 111.1, 65.5, 14.8. HRMS (positive ESI): calcd for $\text{C}_{20}\text{H}_{19}\text{N}_2\text{O}_3$ [M + H], 335.1396; found, 335.1392.

2-(4-Chloro-2-ethoxybenzamido)pyridine 1-Oxide (3ga).

Purified by analytical TLC on silica gel with $\text{CH}_2\text{Cl}_2/\text{acetone}$ (3:1) as an eluent ($R_f = 0.36$) to afford a white solid (29 mg, 50%, mp 210–211 °C from 1:3 hexane/dichloromethane). ^1H NMR (400 MHz, CDCl_3): δ 12.19 (s, 1H), 8.71 (dd, $J = 8.5, 1.4$ Hz, 1H), 8.30–8.28 (m, 1H), 8.23 (d, $J = 8.5$ Hz, 1H), 7.38–7.34 (m, 1H), 7.10 (dd, $J = 8.5, 1.8$ Hz, 1H), 7.06 (d, $J = 1.8$ Hz, 1H), 7.03–6.99 (m, 1H), 4.34 (q, $J = 7.0$ Hz, 2H), 1.73 (t, $J = 7.0$ Hz, 3H). ^{13}C NMR (100 MHz, CDCl_3): δ 163.0, 157.8, 145.2, 140.2, 137.4, 133.8, 128.0, 121.5, 119.1, 118.7, 115.9, 113.1, 66.0, 14.6. HRMS (positive ESI): calcd for $\text{C}_{14}\text{H}_{14}\text{ClN}_2\text{O}_3$ [M + H], 293.0693; found, 293.0690.

2-(4-Bromo-2-ethoxybenzamido)pyridine 1-Oxide (3ha).

Purified by analytical TLC on silica gel with $\text{CH}_2\text{Cl}_2/\text{acetone}$ (3:1) as an eluent ($R_f = 0.39$) to afford a white solid (36 mg, 53%, mp 195–196 °C from 1:3 hexane/dichloromethane). ^1H NMR (400 MHz, CDCl_3): δ 12.18 (s, 1H), 8.72–8.70 (m, 1H), 8.30–8.28 (m, 1H), 8.14 (d, $J = 8.5$ Hz, 1H), 7.38–7.34 (m, 1H), 7.26 (dd, $J = 8.5, 1.7$ Hz, 1H), 7.22 (d, $J = 1.6$ Hz, 1H), 7.03–6.99 (m, 1H), 4.34 (q, $J = 7.0$ Hz, 2H), 1.73 (t, $J = 7.0$ Hz, 3H). ^{13}C NMR (100 MHz, CDCl_3): δ 163.1, 157.7, 145.2, 137.4, 133.9, 128.6, 128.0, 124.5, 119.5, 118.7, 116.0, 115.8, 66.0, 14.6. HRMS (positive ESI): calcd for $\text{C}_{14}\text{H}_{14}\text{BrN}_2\text{O}_3$ [M + H], 337.0188; found, 337.0184.

2-(2-Ethoxy-4-iodobenzamido)pyridine 1-Oxide (3ia). Purified by analytical TLC on silica gel with $\text{CH}_2\text{Cl}_2/\text{acetone}$ (3:1) as an eluent ($R_f = 0.39$) to afford a white solid (45 mg, 58%, mp 163–164 °C from 1:3 hexane/dichloromethane). ^1H NMR (400 MHz, CDCl_3): δ 12.17 (s, 1H), 8.72–8.69 (m, 1H), 8.29–8.28 (m, 1H), 7.96 (d, $J = 8.3$ Hz, 1H), 7.47 (dd, $J = 8.3, 1.3$ Hz, 1H), 7.40 (d, $J = 1.1$ Hz, 1H), 7.37–7.33 (m, 1H), 7.03–6.99 (m, 1H), 4.33 (q, $J = 7.0$ Hz, 2H), 1.72 (t, $J = 7.0$ Hz, 3H). ^{13}C NMR (100 MHz, CDCl_3): δ 163.3, 157.3, 145.2, 137.4, 133.8, 130.6, 127.9, 121.9, 120.2, 118.7, 115.8, 101.1, 66.0, 14.7. HRMS (positive ESI): calcd for $\text{C}_{14}\text{H}_{14}\text{IN}_2\text{O}_3$ [M + H], 385.0049; found, 385.0044.

2-(2-Ethoxy-3,4,5-trimethoxybenzamido)pyridine 1-Oxide (3ja).

Purified by analytical TLC on silica gel with $\text{CH}_2\text{Cl}_2/\text{acetone}$ (3:1) as an eluent ($R_f = 0.45$) to afford a white solid (48 mg, 69%, mp 98–99 °C from 1:5 hexane/dichloromethane). ^1H NMR (400 MHz, CDCl_3): δ 12.58 (s, 1H), 8.69 (dd, $J = 8.5, 1.7$ Hz, 1H), 8.30 (dd, $J = 6.5, 1.1$ Hz, 1H), 7.53 (s, 1H), 7.39–7.34 (m, 1H), 7.03–6.99 (m,

1H), 4.37 (q, $J = 7.0$ Hz, 2H), 4.00 (s, 3H), 3.94 (s, 3H), 3.93 (s, 3H), 1.58 (t, $J = 7.0$ Hz, 3H). ^{13}C NMR (100 MHz, CDCl_3): δ 163.4, 149.3, 147.5, 146.8, 146.4, 145.2, 137.4, 127.7, 119.5, 118.6, 115.7, 107.9, 71.3, 61.4, 61.3, 56.1, 15.5. HRMS (positive ESI): calcd for $\text{C}_{17}\text{H}_{21}\text{N}_2\text{O}_6$ [M + H], 349.1400; found, 349.1392.

2-(2-Ethoxy-5-(trifluoromethyl)benzamido)pyridine 1-Oxide (3ka).

Purified by analytical TLC on silica gel with $\text{CH}_2\text{Cl}_2/\text{acetone}$ (3:1) as an eluent ($R_f = 0.41$) to afford a white solid (38 mg, 59%, mp 190–191 °C from 1:5 hexane/dichloromethane). ^1H NMR (400 MHz, CDCl_3): δ 12.25 (s, 1H), 8.73–8.71 (m, 1H), 8.59–8.58 (m, 1H), 8.30–8.29 (m, 1H), 7.77 (dd, $J = 8.7, 2.2$ Hz, 1H), 7.40–7.36 (m, 1H), 7.17 (d, $J = 8.7$ Hz, 1H), 7.05–7.02 (m, 1H), 4.41 (q, $J = 7.0$ Hz, 2H), 1.75 (t, $J = 7.0$ Hz, 3H). ^{13}C NMR (100 MHz, CDCl_3): δ 161.5, 158.5, 144.0, 136.3, 130.0 (q, $J_{\text{C}-\text{F}} = 3.4$ Hz), 129.3 (q, $J_{\text{C}-\text{F}} = 3.7$ Hz), 127.0, 122.8 (q, $J_{\text{C}-\text{F}} = 269.9$ Hz), 122.5 (q, $J_{\text{C}-\text{F}} = 33.3$ Hz), 119.8, 117.9, 114.9, 111.8, 65.1, 13.6. ^{19}F NMR (376 MHz, CDCl_3): δ –61.92. HRMS (positive ESI): calcd for $\text{C}_{15}\text{H}_{14}\text{F}_3\text{N}_2\text{O}_3$ [M + H], 327.0957; found, 327.0953.

2-(2-Ethoxy-4-methoxybenzamido)pyridine 1-Oxide (3la).

Purified by analytical TLC on silica gel with $\text{CH}_2\text{Cl}_2/\text{acetone}$ (2:1) as an eluent ($R_f = 0.29$) to afford a white solid (50 mg, 87%, mp 196–197 °C from 1:5 hexane/dichloromethane). ^1H NMR (400 MHz, CDCl_3): δ 12.16 (s, 1H), 8.74 (dd, $J = 8.5, 1.3$ Hz, 1H), 8.29–8.27 (m, 1H), 8.24 (d, $J = 8.9$ Hz, 1H), 7.36–7.32 (m, 1H), 6.99–6.96 (m, 1H), 6.63 (dd, $J = 8.8, 2.2$ Hz, 1H), 6.54 (d, $J = 2.2$ Hz, 1H), 4.31 (q, $J = 7.0$ Hz, 2H), 3.83 (s, 3H), 1.72 (t, $J = 7.0$ Hz, 3H). ^{13}C NMR (100 MHz, CDCl_3): δ 164.6, 163.7, 159.0, 145.6, 137.3, 134.4, 128.1, 118.1, 115.7, 113.5, 105.7, 99.1, 65.4, 55.6, 14.7. HRMS (positive ESI): calcd for $\text{C}_{15}\text{H}_{17}\text{N}_2\text{O}_4$ [M + H], 289.1188; found, 289.1185.

2-(2-Butoxybenzamido)pyridine 1-Oxide (3ab).

Purified by analytical TLC on silica gel with $\text{CH}_2\text{Cl}_2/\text{acetone}$ (10:1) as an eluent ($R_f = 0.40$) to afford a white solid (50 mg, 87%, mp 90–91 °C from 1:5 hexane/dichloromethane). ^1H NMR (400 MHz, CDCl_3): δ 12.26 (s, 1H), 8.73 (dd, $J = 8.5, 1.7$ Hz, 1H), 8.30–8.27 (m, 2H), 7.55–7.51 (m, 1H), 7.37–7.33 (m, 1H), 7.13–7.07 (m, 2H), 7.01–6.97 (m, 1H), 4.29 (t, $J = 7.1$ Hz, 2H), 2.14–2.07 (m, 2H), 1.60–1.50 (m, 2H), 1.02 (t, $J = 7.4$ Hz, 3H). ^{13}C NMR (100 MHz, CDCl_3): δ 164.0, 157.6, 145.4, 137.4, 134.3, 132.7, 127.7, 121.0, 120.6, 118.5, 115.8, 112.5, 69.6, 30.6, 19.3, 13.8. HRMS (positive ESI): calcd for $\text{C}_{16}\text{H}_{19}\text{N}_2\text{O}_3$ [M + H], 287.1396; found, 287.1401.

2-(2-(2-Thiophen-2-yl)ethoxybenzamido)pyridine 1-Oxide (3ac).

Purified by analytical TLC on silica gel with $\text{CH}_2\text{Cl}_2/\text{acetone}$ (5:1) as an eluent ($R_f = 0.30$) to afford a white solid (50 mg, 73%, mp 123–124 °C from 1:5 hexane/dichloromethane). ^1H NMR (400 MHz, CDCl_3): δ 12.26 (s, 1H), 8.74 (dd, $J = 8.4, 1.1$ Hz, 1H), 8.30–8.26 (m, 2H), 7.53–7.49 (m, 1H), 7.38–7.34 (m, 1H), 7.14–7.10 (m, 2H), 7.04–6.99 (m, 2H), 6.97–6.96 (m, 1H), 6.93–6.91 (m, 1H), 4.45 (t, $J = 7.3$ Hz, 2H), 3.70 (t, $J = 7.2$ Hz, 2H). ^{13}C NMR (100 MHz, CDCl_3): δ 163.8, 157.1, 145.3, 139.7, 137.3, 134.3, 132.7, 127.8, 126.9, 126.1, 124.1, 121.5, 120.7, 118.5, 115.8, 112.5, 70.4, 29.6. HRMS (positive ESI): calcd for $\text{C}_{18}\text{H}_{17}\text{N}_2\text{O}_3\text{S}$ [M + H], 341.0960; found, 341.0955.

2-(2-Methylbutoxy)benzamido)pyridine 1-Oxide (3ad).

Purified by analytical TLC on silica gel with $\text{CH}_2\text{Cl}_2/\text{acetone}$ (6:1) as an eluent ($R_f = 0.30$) to afford a white solid (45 mg, 75%, mp 117–118 °C from 1:5 hexane/dichloromethane). ^1H NMR (400 MHz, CDCl_3): δ 12.19 (s, 1H), 8.73 (dd, $J = 8.5, 1.8$ Hz, 1H), 8.30–8.25 (m, 2H), 7.54–7.50 (m, 1H), 7.36–7.32 (m, 1H), 7.12–7.06 (m, 2H), 7.01–6.97 (m, 1H), 4.19–4.15 (m, 1H), 4.04–3.99 (m, 1H), 2.39–2.31 (m, 1H), 1.66–1.56 (m, 1H), 1.40–1.29 (m, 1H), 1.09 (d, $J = 6.7$ Hz, 3H), 0.98 (t, $J = 7.4$ Hz, 3H). ^{13}C NMR (100 MHz, CDCl_3): δ 164.1, 157.7, 145.3, 137.4, 134.2, 132.6, 127.5, 121.0, 120.7, 118.5, 115.8, 112.6, 74.9, 33.7, 26.3, 16.8, 11.0. HRMS (positive ESI): calcd for $\text{C}_{17}\text{H}_{21}\text{N}_2\text{O}_3$ [M + H], 301.1552; found, 301.1547.

2-(2-But-3-en-1-yloxy)benzamido)pyridine 1-Oxide (3ae).

Purified by analytical TLC on silica gel with $\text{CH}_2\text{Cl}_2/\text{acetone}$ (10:1) as an eluent ($R_f = 0.29$) to afford a white solid (42 mg, 74%, mp 107–108 °C from 1:5 hexane/dichloromethane). ^1H NMR (400 MHz, CDCl_3): δ 12.23 (s, 1H), 8.73 (dd, $J = 8.5, 1.7$ Hz, 1H), 8.30–8.27 (m, 2H), 7.55–7.51 (m, 1H), 7.37–7.33 (m, 1H), 7.14–7.06 (m, 2H),

7.01–6.98 (m, 1H), 6.02–5.92 (m, 1H), 5.24–5.19 (m, 1H), 5.13–5.10 (m, 1H), 4.31 (t, J = 7.2 Hz, 2H), 2.93–2.88 (m, 2H). ^{13}C NMR (100 MHz, CDCl_3): δ 163.9, 157.3, 145.4, 137.3, 134.3, 133.8, 132.7, 127.7, 121.2, 120.6, 118.5, 117.6, 115.8, 112.5, 69.0, 33.1. HRMS (positive ESI): calcd for $\text{C}_{16}\text{H}_{17}\text{N}_2\text{O}_3$ [M + H], 285.1239; found, 285.1237.

2-(2-Phenethoxybenzamido)pyridine 1-Oxide (3af). Purified by analytical TLC on silica gel with CH_2Cl_2 /acetone (5:1) as an eluent (R_f = 0.33) to afford a white solid (44 mg, 66%, mp 153–154 °C from 1:5 hexane/dichloromethane). ^1H NMR (400 MHz, CDCl_3): δ 12.28 (s, 1H), 8.74 (dd, J = 8.5, 1.6 Hz, 1H), 8.32–8.26 (m, 2H), 7.52–7.48 (m, 1H), 7.39–7.27 (m, 5H), 7.24–7.20 (m, 1H), 7.13–7.10 (m, 1H), 7.03–6.99 (m, 2H), 4.42 (t, J = 7.8 Hz, 2H), 3.47 (t, J = 7.9 Hz, 2H). ^{13}C NMR (100 MHz, CDCl_3): δ 163.9, 157.3, 145.3, 137.5, 137.4, 134.3, 132.7, 129.2, 129.0, 128.5, 127.9, 126.6, 126.4, 121.3, 120.7, 118.6, 115.8, 112.6, 70.7, 35.5. HRMS (positive ESI): calcd for $\text{C}_{20}\text{H}_{19}\text{N}_2\text{O}_3$ [M + H], 335.1396; found, 335.1392.

2-(2-Methoxyethoxy)benzamido)pyridine 1-Oxide (3ag). Purified by analytical TLC on silica gel with CH_2Cl_2 /acetone (2:1) as an eluent (R_f = 0.44) to afford a white solid (40 mg, 70%, mp 114–115 °C from 1:5 hexane/dichloromethane). ^1H NMR (400 MHz, CDCl_3): δ 12.24 (s, 1H), 8.72 (dd, J = 8.5, 1.8 Hz, 1H), 8.30–8.27 (m, 2H), 7.56–7.51 (m, 1H), 7.37–7.33 (m, 1H), 7.15–7.10 (m, 2H), 7.01–6.97 (m, 1H), 4.42 (t, J = 4.7 Hz, 2H), 4.10 (t, J = 4.9 Hz, 2H), 3.48 (s, 3H). ^{13}C NMR (100 MHz, CDCl_3): δ 163.8, 157.4, 145.4, 137.3, 134.3, 132.7, 127.6, 121.5, 120.8, 118.5, 115.8, 112.8, 70.4, 69.0, 59.1. HRMS (positive ESI): calcd for $\text{C}_{15}\text{H}_{17}\text{N}_2\text{O}_4$ [M + H], 289.1188; found, 289.1185.

2-(2-Isopropoxybenzamido)pyridine 1-Oxide (3ah). Purified by analytical TLC on silica gel with CH_2Cl_2 /acetone (5:1) as an eluent (R_f = 0.40) to afford a white solid (39 mg, 71%, mp 138–139 °C from 1:5 hexane/dichloromethane). ^1H NMR (400 MHz, CDCl_3): δ 12.28 (s, 1H), 8.75 (dd, J = 8.5, 1.8 Hz, 1H), 8.31–8.28 (m, 2H), 7.54–7.50 (m, 1H), 7.37–7.33 (m, 1H), 7.11–7.07 (m, 2H), 7.01–6.97 (m, 1H), 4.96–4.90 (m, 1H), 1.60 (d, J = 6.1 Hz, 6H). ^{13}C NMR (100 MHz, CDCl_3): δ 164.1, 156.5, 145.4, 137.4, 134.2, 132.8, 127.7, 121.2, 120.9, 118.5, 115.9, 113.6, 72.3, 21.9. HRMS (positive ESI): calcd for $\text{C}_{15}\text{H}_{17}\text{N}_2\text{O}_3$ [M + H], 273.1239; found, 273.1237.

2-((1*R*,2*R*,5*R*)-2-Isopropyl-5-methylcyclohexyl)oxy)benzamido)pyridine 1-Oxide (3ai). Purified by analytical TLC on silica gel with CH_2Cl_2 /acetone (10:1) as an eluent (R_f = 0.49) to afford a white solid (28 mg, 38%, mp 133–134 °C from 1:2 hexane/dichloromethane). ^1H NMR (400 MHz, CDCl_3): δ 12.29 (s, 1H), 8.74 (dd, J = 8.5, 1.7 Hz, 1H), 8.31–8.28 (m, 2H), 7.53–7.49 (m, 1H), 7.34–7.30 (m, 1H), 7.13–7.06 (m, 2H), 6.99–6.95 (m, 1H), 4.45–4.39 (m, 1H), 2.25–2.16 (m, 3H), 1.83–1.79 (m, 1H), 1.73–1.72 (m, 1H), 1.52–1.49 (m, 1H), 1.44–1.38 (m, 1H), 1.15–1.10 (m, 2H), 0.95 (d, J = 3.0 Hz, 3H), 0.93 (d, J = 2.5 Hz, 3H), 0.76 (d, J = 6.9 Hz, 3H). ^{13}C NMR (100 MHz, CDCl_3): δ 164.2, 157.1, 145.4, 137.4, 134.3, 132.9, 127.3, 121.2, 120.7, 118.4, 115.8, 113.3, 79.7, 46.4, 39.9, 34.0, 31.7, 26.3, 23.6, 22.0, 20.6, 16.5. HRMS (positive ESI): calcd for $\text{C}_{22}\text{H}_{29}\text{N}_2\text{O}_3$ [M + H], 369.2178; found, 369.2178.

2-(2-*n*-Decoxymethylbenzamido)pyridine 1-Oxide (3aj). Purified by analytical TLC on silica gel with CH_2Cl_2 /acetone (10:1) as an eluent (R_f = 0.45) to afford a white solid (42 mg, 57%, mp 83–84 °C from 1:3 hexane/dichloromethane). ^1H NMR (400 MHz, CDCl_3): δ 12.27 (s, 1H), 8.73 (dd, J = 8.5, 1.7 Hz, 1H), 8.30–8.26 (m, 2H), 7.55–7.50 (m, 1H), 7.37–7.32 (m, 1H), 7.12–7.06 (m, 2H), 7.01–6.97 (m, 1H), 4.27 (t, J = 7.2 Hz, 2H), 2.15–2.08 (m, 2H), 1.52–1.49 (m, 2H), 1.42–1.35 (m, 2H), 1.28–1.24 (m, 10H), 0.87 (t, J = 7.0 Hz, 3H). ^{13}C NMR (100 MHz, CDCl_3): δ 164.1, 157.6, 145.4, 137.3, 134.3, 132.6, 127.6, 121.0, 120.6, 118.5, 115.8, 112.5, 69.9, 31.9, 29.6, 29.5, 29.3, 29.2, 28.6, 26.0, 22.7, 14.1. HRMS (positive ESI): calcd for $\text{C}_{22}\text{H}_{31}\text{N}_2\text{O}_3$ [M + H], 371.2335; found, 371.2332.

2-(Dodecoxybenzamido)pyridine 1-Oxide (3ak). Purified by analytical TLC on silica gel with CH_2Cl_2 /acetone (10:1) as an eluent (R_f = 0.45) to afford a white solid (48 mg, 60%, mp 78–79 °C from 1:2 hexane/dichloromethane). ^1H NMR (400 MHz, CDCl_3): δ 12.27 (s, 1H), 8.73 (dd, J = 8.5, 1.7 Hz, 1H), 8.30–8.26 (m, 2H), 7.55–7.50 (m, 1H), 7.37–7.32 (m, 1H), 7.13–7.06 (m, 2H), 7.01–6.97 (m, 1H),

4.27 (t, J = 7.2 Hz, 2H), 2.15–2.08 (m, 2H), 1.51–1.45 (m, 2H), 1.42–1.35 (m, 2H), 1.29–1.24 (m, 14H), 0.88 (t, J = 7.0 Hz, 3H). ^{13}C NMR (100 MHz, CDCl_3): δ 164.1, 157.6, 145.4, 137.3, 134.3, 132.6, 127.6, 121.0, 120.6, 118.5, 115.8, 112.5, 69.9, 31.9, 29.6, 29.4, 29.2, 28.6, 26.0, 22.7, 14.1. HRMS (positive ESI): calcd for $\text{C}_{24}\text{H}_{35}\text{N}_2\text{O}_3$ [M + H], 399.2648; found, 399.2645.

2-(2-((Hexafluoropropan-2-yl)oxy)benzamido)pyridine 1-Oxide (3al). Purified by analytical TLC on silica gel with petroleum ether/ethyl acetate (1:1) as an eluent (R_f = 0.30 and 0.38 for 3al and 3'al, respectively) to afford a white solid (52 mg, 68%, and mp 138–139 °C from 1:2 hexane/dichloromethane for 3al; 26 mg, 24%, and mp 196–197 °C from 1:2 hexane/dichloromethane for 3'al). ^1H NMR (400 MHz, CDCl_3): δ 11.22 (s, 1H), 8.63 (dd, J = 8.5, 1.8 Hz, 1H), 8.32–8.30 (m, 1H), 8.09–8.06 (m, 1H), 7.62–7.58 (m, 1H), 7.39–7.31 (m, 2H), 7.17 (d, J = 8.4 Hz, 1H), 7.05–7.01 (m, 1H), 5.14–5.08 (m, 1H). ^{13}C NMR (100 MHz, CDCl_3): δ 163.1, 154.7, 144.5, 137.3, 134.0, 132.3, 127.6, 125.1, 125.0, 120.7 (q, $J_{\text{C}-\text{F}} = 285.8$ Hz), 119.0, 115.4, 115.3, 76.4 (p, $J_{\text{C}-\text{F}} = 33.8$ Hz). ^{19}F NMR (376 MHz, CDCl_3): δ –72.78. HRMS (positive ESI): calcd for $\text{C}_{15}\text{H}_{11}\text{F}_6\text{N}_2\text{O}_3$ [M + H], 381.0674; found, 381.0672.

2-(2,6-Bis(hexafluoropropan-2-yl)oxy)benzamido)pyridine 1-Oxide (3'al). ^1H NMR (400 MHz, DMSO-d_6): δ 8.41–8.37 (m, 2H), 7.70–7.66 (m, 1H), 7.52–7.49 (m, 1H), 7.29 (d, J = 8.6 Hz, 2H), 7.24–7.21 (m, 1H), 6.67–6.63 (m, 2H). ^{13}C NMR (100 MHz, DMSO-d_6): δ 161.0, 153.4, 142.9, 137.6, 132.0, 127.4, 121.0 (q, $J_{\text{C}-\text{F}} = 285.8$ Hz), 120.1, 118.0, 114.2, 109.8, 72.6 (p, $J_{\text{C}-\text{F}} = 32.4$ Hz). ^{19}F NMR (376 MHz, DMSO-d_6): δ –72.90. HRMS (positive ESI): calcd for $\text{C}_{18}\text{H}_{11}\text{F}_{12}\text{N}_2\text{O}_4$ [M + H], 547.0527; found, 547.0526.

2-(2-((Hexafluoropropan-2-yl)oxy)-5-methylbenzamido)pyridine 1-Oxide (3el). Purified by analytical TLC on silica gel with CH_2Cl_2 /acetone (10:1) as an eluent (R_f = 0.33) to afford a white solid (69 mg, 88%, mp 159–160 °C from 1:4 hexane/dichloromethane). ^1H NMR (400 MHz, CDCl_3): δ 11.20 (s, 1H), 8.63 (dd, J = 8.5, 1.8 Hz, 1H), 8.30 (d, J = 6.2 Hz, 1H), 7.85 (d, J = 2.0 Hz, 1H), 7.38–7.34 (m, 2H), 7.07–7.01 (m, 2H), 5.09–5.04 (m, 1H), 2.39 (s, 3H). ^{13}C NMR (100 MHz, CDCl_3): δ 163.3, 152.7, 144.6, 137.3, 135.0, 134.5, 132.4, 127.6, 124.6, 120.8 (q, $J_{\text{C}-\text{F}} = 285.2$ Hz), 118.9, 115.5, 115.3, 76.7 (p, $J_{\text{C}-\text{F}} = 34.0$ Hz), 20.5. ^{19}F NMR (376 MHz, CDCl_3): δ –72.84. HRMS (positive ESI): calcd for $\text{C}_{16}\text{H}_{13}\text{F}_6\text{N}_2\text{O}_3$ [M + H], 395.0830; found, 395.0828.

2-(2-((Hexafluoropropan-2-yl)oxy)-4-iodobenzamido)pyridine 1-Oxide (3il). Purified by analytical TLC on silica gel with petroleum ether/ethyl acetate (1:1) as an eluent (R_f = 0.28 and 0.60 for 3al and 3'il, respectively) to afford a white solid (54 mg, 53%, and mp 99–100 °C from 1:4 hexane/dichloromethane for 3il; 38 mg, 28%, and mp 138–139 °C from 1:4 hexane/dichloromethane for 3'il). ^1H NMR (400 MHz, CDCl_3): δ 11.21 (s, 1H), 8.60 (dd, J = 8.5, 1.5 Hz, 1H), 8.31–8.30 (m, 1H), 7.78 (d, J = 8.2 Hz, 1H), 7.70–7.68 (m, 1H), 7.50 (s, 1H), 7.39–7.35 (m, 1H), 7.06–7.02 (m, 1H), 5.13–5.09 (m, 1H). ^{13}C NMR (100 MHz, CDCl_3): δ 162.4, 154.4, 144.3, 137.3, 134.6, 133.4, 127.6, 124.7, 124.5, 120.7 (q, $J_{\text{C}-\text{F}} = 280.0$ Hz), 119.2, 115.4, 99.6, 76.5 (p, $J_{\text{C}-\text{F}} = 33.4$ Hz). ^{19}F NMR (376 MHz, CDCl_3): δ –72.66. HRMS (positive ESI): calcd for $\text{C}_{15}\text{H}_{10}\text{F}_6\text{IN}_2\text{O}_3$ [M + H], 506.9640; found, 506.9644.

2-(2,6-Bis(hexafluoropropan-2-yl)oxy)-4-iodobenzamido)pyridine 1-Oxide (3'il). ^1H NMR (400 MHz, DMSO-d_6): δ 8.39–8.33 (m, 2H), 7.72 (s, 2H), 7.50–7.46 (m, 1H), 7.24–7.20 (m, 1H), 6.72–6.66 (m, 2H). ^{13}C NMR (100 MHz, DMSO-d_6): δ 160.7, 153.4, 143.0, 137.7, 127.2, 120.8 (q, $J_{\text{C}-\text{F}} = 282.4$ Hz), 120.2, 118.5, 118.0, 114.6, 96.7, 72.5 (p, $J_{\text{C}-\text{F}} = 32.8$ Hz). ^{19}F NMR (376 MHz, DMSO-d_6): δ –72.91. HRMS (positive ESI): calcd for $\text{C}_{18}\text{H}_{10}\text{F}_{12}\text{IN}_2\text{O}_4$ [M + H], 672.9499; found, 672.9493.

2-(2-((Hexafluoropropan-2-yl)oxy)-5-(trifluoromethyl)benzamido)pyridine 1-Oxide (3kl). Purified by analytical TLC on silica gel with CH_2Cl_2 /acetone (6:1) as an eluent (R_f = 0.45) to afford a white solid (84 mg, 94%, mp 110–111 °C from 1:4 hexane/dichloromethane). ^1H NMR (400 MHz, CDCl_3): δ 11.30 (s, 1H), 8.62 (dd, J = 8.5, 1.7 Hz, 1H), 8.40 (d, J = 2.1 Hz, 1H), 8.32–8.30 (m, 1H), 7.86 (dd, J = 8.8, 2.2 Hz, 1H), 7.41–7.37 (m, 1H), 7.30 (d, J = 8.8 Hz, 1H), 7.09–7.05 (m, 1H), 5.25–5.20 (m, 1H). ^{13}C NMR

(100 MHz, CDCl_3): δ 161.6, 156.4, 144.1, 137.2, 130.9 ($q, J_{\text{C}-\text{F}} = 3.4$ Hz), 130.1 ($q, J_{\text{C}-\text{F}} = 3.4$ Hz), 127.7, 127.4 ($q, J_{\text{C}-\text{F}} = 33.7$ Hz), 125.2, 123.1 ($q, J_{\text{C}-\text{F}} = 270.7$ Hz), 120.5 ($q, J_{\text{C}-\text{F}} = 282.4$ Hz), 119.5, 115.5, 115.4, 75.8 ($p, J_{\text{C}-\text{F}} = 34.1$ Hz). ^{19}F NMR (376 MHz, CDCl_3): δ -62.45, -72.62. HRMS (positive ESI): calcd for $\text{C}_{16}\text{H}_{10}\text{F}_9\text{N}_2\text{O}_3$ [M + H], 449.0548; found, 449.0553.

2-(2-((Hexafluoropropan-2-yl)oxy)-4-methoxybenzamido)-pyridine 1-Oxide (3ll). Purified by analytical TLC on silica gel with petroleum ether/ethyl acetate (1:1) as an eluent ($R_f = 0.23$ and 0.50 for 3ll and 3'll, respectively) to afford a white solid (23 mg, 28%, and mp 157–158 °C from 1:4 hexane/dichloromethane for 3ll; 69 mg, 60%, and mp 182–183 °C from 1:4 hexane/dichloromethane for 3'll). ^1H NMR (400 MHz, CDCl_3): δ 11.28 (s, 1H), 8.63 (dd, $J = 8.4, 1.4$ Hz, 1H), 8.31–8.29 (m, 1H), 8.12 (d, $J = 8.8$ Hz, 1H), 7.34–7.32 (m, 1H), 7.02–6.99 (m, 1H), 6.83–6.81 (m, 1H), 6.65 (d, $J = 2.1$ Hz, 1H), 5.21–5.15 (m, 1H), 3.89 (s, 3H). ^{13}C NMR (100 MHz, CDCl_3): δ 164.3, 162.7, 156.1, 144.8, 137.3, 134.5, 127.6, 120.7 ($q, J_{\text{C}-\text{F}} = 285.3$ Hz), 118.7, 116.8, 115.4, 109.2, 101.9, 76.1 ($p, J_{\text{C}-\text{F}} = 34.0$ Hz), 55.9. ^{19}F NMR (376 MHz, CDCl_3): δ -72.67. HRMS (positive ESI): calcd for $\text{C}_{16}\text{H}_{13}\text{F}_6\text{N}_2\text{O}_4$ [M + H], 411.0780; found, 411.0784.

2-(2,6-Bis((hexafluoropropan-2-yl)oxy)-4-methoxybenzamido)-pyridine 1-Oxide (3'll). ^1H NMR (400 MHz, DMSO-d_6): δ 8.42–8.34 (m, 2H), 7.52–7.48 (m, 1H), 7.23–7.20 (m, 1H), 6.91 (s, 2H), 6.71–6.65 (m, 2H), 3.90 (s, 3H). ^{13}C NMR (100 MHz, DMSO-d_6): δ 162.2, 160.7, 154.4, 143.0, 137.4, 127.5, 120.9 ($q, J_{\text{C}-\text{F}} = 281.7$ Hz), 119.8, 113.9, 110.5, 96.2, 72.3 ($p, J_{\text{C}-\text{F}} = 32.5$ Hz), 56.3. ^{19}F NMR (376 MHz, DMSO-d_6): δ -72.94. HRMS (positive ESI): calcd for $\text{C}_{19}\text{H}_{13}\text{F}_{12}\text{N}_2\text{O}_5$ [M + H], 577.0633; found, 577.0638.

2-(2-((Hexafluoropropan-2-yl)oxy)-4-(methylsulfonyl)-benzamido)pyridine 1-Oxide (3ml). Purified by analytical TLC on silica gel with petroleum ether/ethyl acetate (1:1) as an eluent ($R_f = 0.25$ and 0.55 for 3ml and 3'ml, respectively) to afford a white solid (64 mg, 70%, and mp 206–207 °C from 1:4 hexane/dichloromethane for 3ml; 27 mg, 22%, and mp 291–292 °C from 1:4 hexane/dichloromethane for 3'ml). ^1H NMR (400 MHz, DMSO-d_6): δ 8.45–8.41 (m, 2H), 8.08 (d, $J = 8.0$ Hz, 1H), 8.04 (d, $J = 1.0$ Hz, 1H), 7.90–7.88 (m, 1H), 7.53–7.48 (m, 1H), 7.26–7.22 (m, 1H), 6.95–6.89 (m, 1H), 3.35 (s, 3H). ^{13}C NMR (100 MHz, DMSO-d_6): δ 162.2, 153.2, 144.6, 143.1, 137.5, 132.0, 129.6, 127.3, 122.9, 120.9 ($q, J_{\text{C}-\text{F}} = 282.3$ Hz), 120.3, 114.9, 114.2, 73.5 ($p, J_{\text{C}-\text{F}} = 33.0$ Hz), 43.2. ^{19}F NMR (376 MHz, DMSO-d_6): δ -72.44. HRMS (positive ESI): calcd for $\text{C}_{16}\text{H}_{13}\text{F}_6\text{N}_2\text{O}_3\text{S}$ [M + H], 459.0449; found, 459.0456.

2-(2,6-Bis((hexafluoropropan-2-yl)oxy)-4-(methylsulfonyl)-benzamido)pyridine 1-Oxide (3'ml). ^1H NMR (400 MHz, DMSO-d_6): δ 8.38–8.36 (m, 2H), 7.82 (s, 2H), 7.50–7.46 (m, 1H), 7.25–7.21 (m, 1H), 6.89–6.83 (m, 2H), 3.35 (s, 3H). ^{13}C NMR (100 MHz, DMSO-d_6): δ 160.4, 153.7, 143.7, 143.1, 137.9, 127.1, 122.7, 120.8 ($q, J_{\text{C}-\text{F}} = 281.0$ Hz), 114.9, 110.5, 108.6, 72.8 ($p, J_{\text{C}-\text{F}} = 33.0$ Hz), 43.2. ^{19}F NMR (376 MHz, DMSO-d_6): δ -72.77. HRMS (positive ESI): calcd for $\text{C}_{19}\text{H}_{13}\text{F}_{12}\text{N}_2\text{O}_6\text{S}$ [M + H], 625.0303; found, 625.0305.

2-(2-((Hexafluoropropan-2-yl)oxy)-4-(methoxycarbonyl)-benzamido)pyridine 1-Oxide (3nl). Purified by analytical TLC on silica gel with petroleum ether/ethyl acetate (1:1) as an eluent ($R_f = 0.22$ and 0.46 for 3nl and 3'nl, respectively) to afford a white solid (49 mg, 56%, and mp 173–174 °C from 1:4 hexane/dichloromethane for 3nl; 28 mg, 23%, and mp 163–164 °C from 1:4 hexane/dichloromethane for 3'nl). ^1H NMR (400 MHz, CDCl_3): δ 11.24 (s, 1H), 8.62 (dd, $J = 8.5, 1.6$ Hz, 1H), 8.33–8.31 (m, 1H), 8.14 (d, $J = 8.1$ Hz, 1H), 7.97–7.95 (m, 1H), 7.83 (s, 1H), 7.40–7.36 (m, 1H), 7.08–7.04 (m, 1H), 5.29–5.24 (m, 1H), 3.98 (s, 3H). ^{13}C NMR (100 MHz, CDCl_3): δ 165.0, 162.3, 154.2, 144.2, 137.3, 135.2, 132.6, 128.6, 127.6, 125.7, 120.6 ($q, J_{\text{C}-\text{F}} = 282.0$ Hz), 119.3, 115.8, 115.4, 75.9 ($p, J_{\text{C}-\text{F}} = 34.0$ Hz), 52.9. ^{19}F NMR (376 MHz, CDCl_3): δ -72.72. HRMS (positive ESI): calcd for $\text{C}_{17}\text{H}_{13}\text{F}_6\text{N}_2\text{O}_5$ [M + H], 439.0729; found, 439.0727.

2-(2,6-Bis((hexafluoropropan-2-yl)oxy)-4-(methoxycarbonyl)-benzamido)pyridine 1-Oxide (3'nl). ^1H NMR (400 MHz, CDCl_3): δ 10.30 (s, 1H), 8.57 (dd, $J = 8.4, 1.4$ Hz, 1H), 8.29–8.27 (m, 1H), 7.58 (s, 2H), 7.44–7.39 (m, 1H), 7.10–7.06 (m, 1H), 5.11–5.05 (m, 2H), 4.01 (s, 3H). ^{13}C NMR (100 MHz, CDCl_3): δ 164.2, 159.8,

154.6, 143.5, 137.2, 134.2, 128.1, 123.2, 120.5 ($q, J_{\text{C}-\text{F}} = 282.7$ Hz), 119.6, 114.9, 111.5, 75.6 ($p, J_{\text{C}-\text{F}} = 33.9$ Hz), 53.3. ^{19}F NMR (376 MHz, CDCl_3): δ -73.04. HRMS (positive ESI): calcd for $\text{C}_{20}\text{H}_{13}\text{F}_{12}\text{N}_2\text{O}_6$ [M + H], 605.0582; found, 605.0583.

2-(3-((Hexafluoropropan-2-yl)oxy)isonicotinamido)pyridine 1-Oxide (3ol).

Purified by analytical TLC on silica gel with petroleum ether/ethyl acetate (1:1) as an eluent ($R_f = 0.22$ and 0.60 for 3ol and 3'ol, respectively) to afford a white solid (41 mg, 54%, and mp 138–139 °C from 1:4 hexane/dichloromethane for 3ol; 23 mg, 21%, and mp 250–251 °C from 1:4 hexane/dichloromethane for 3'ol). ^1H NMR (400 MHz, CDCl_3): δ 11.24 (s, 1H), 8.68–8.65 (m, 2H), 8.59 (dd, $J = 8.4, 1.6$ Hz, 1H), 8.32–8.31 (m, 1H), 7.90 (d, $J = 4.7$ Hz, 1H), 7.42–7.38 (m, 1H), 7.11–7.07 (m, 1H), 5.31–5.25 (m, 1H). ^{13}C NMR (100 MHz, CDCl_3): δ 161.1, 149.9, 147.0, 143.9, 139.1, 137.3, 131.7, 127.7, 124.3, 120.5 ($q, J_{\text{C}-\text{F}} = 280.0$ Hz), 119.7, 115.5, 76.9 ($p, J_{\text{C}-\text{F}} = 34.1$ Hz). ^{19}F NMR (376 MHz, CDCl_3): δ -72.77. HRMS (positive ESI): calcd for $\text{C}_{14}\text{H}_{10}\text{F}_6\text{N}_3\text{O}_3$ [M + H], 382.0626; found, 382.0623.

2-(2,6-Bis((hexafluoropropan-2-yl)oxy)isonicotinamido)pyridine 1-Oxide (3'ol).

^1H NMR (400 MHz, DMSO-d_6): δ 8.62 (s, 2H), 8.39–8.35 (m, 2H), 7.50–7.46 (m, 1H), 7.26–7.22 (m, 1H), 6.82–6.76 (m, 2H). ^{13}C NMR (100 MHz, DMSO-d_6): δ 159.6, 149.0, 143.0, 138.0, 127.0, 125.3, 120.8 ($q, J_{\text{C}-\text{F}} = 279.8$ Hz), 120.6, 115.2, 73.3 ($p, J_{\text{C}-\text{F}} = 32.8$ Hz). ^{19}F NMR (376 MHz, DMSO-d_6): δ -72.85. HRMS (positive ESI): calcd for $\text{C}_{17}\text{H}_{10}\text{F}_{12}\text{N}_3\text{O}_4$ [M + H], 548.0480; found, 548.0473.

2-(2-((Hexafluoropropan-2-yl)oxy)-4-(trifluoromethyl)-benzamido)pyridine 1-Oxide (3pl).

Purified by analytical TLC on silica gel with CH_2Cl_2 /acetone (10:1) as an eluent ($R_f = 0.40$) to afford a white solid (69 mg, 77%, mp 119–120 °C from 1:1 hexane/dichloromethane). ^1H NMR (400 MHz, CDCl_3): δ 11.19 (s, 1H), 8.62–8.60 (m, 1H), 8.30–8.29 (m, 1H), 8.18–8.16 (m, 1H), 7.60–7.58 (m, 1H), 7.42–7.38 (m, 2H), 7.09–7.05 (m, 1H), 5.26–5.20 (m, 1H). ^{13}C NMR (100 MHz, CDCl_3): δ 161.9, 154.4, 144.1, 137.2, 135.6 ($q, J_{\text{C}-\text{F}} = 33.5$ Hz), 133.1, 128.4, 127.7 ($q, J_{\text{C}-\text{F}} = 271.6$ Hz), 121.9 ($q, J_{\text{C}-\text{F}} = 3.5$ Hz), 120.5 ($q, J_{\text{C}-\text{F}} = 280.9$ Hz), 119.5, 115.4, 112.6, 76.3 ($p, J_{\text{C}-\text{F}} = 34.1$ Hz). ^{19}F NMR (376 MHz, CDCl_3): δ -63.23, -72.76. HRMS (positive ESI): calcd for $\text{C}_{16}\text{H}_{10}\text{F}_9\text{N}_2\text{O}_3$ [M + H], 449.0548; found, 449.0550.

2-(2-((Hexafluoropropan-2-yl)oxy)-6-methylbenzamido)pyridine 1-Oxide (3ql).

Purified by analytical TLC on silica gel with CH_2Cl_2 /acetone (10:1) as an eluent ($R_f = 0.35$) to afford a white solid (73 mg, 93%, mp 95–96 °C from 1:4 hexane/dichloromethane). ^1H NMR (400 MHz, CDCl_3): δ 10.20 (s, 1H), 8.63–8.61 (m, 1H), 8.25–8.24 (m, 1H), 7.42–7.35 (m, 2H), 7.09–7.04 (m, 2H), 6.93 (d, $J = 8.4$ Hz, 1H), 4.97–4.91 (m, 1H), 2.41 (s, 3H). ^{13}C NMR (100 MHz, CDCl_3): δ 164.9, 153.6, 144.0, 138.1, 137.3, 131.1, 128.2, 127.8, 126.7, 120.8 ($q, J_{\text{C}-\text{F}} = 284.9$ Hz), 119.1, 114.9, 112.2, 76.0 ($p, J_{\text{C}-\text{F}} = 33.5$ Hz), 19.2. ^{19}F NMR (376 MHz, CDCl_3): δ -73.20. HRMS (positive ESI): calcd for $\text{C}_{16}\text{H}_{13}\text{F}_6\text{N}_2\text{O}_3$ [M + H], 395.0830; found, 395.0828.

2-(2-Chloro-6-((hexafluoropropan-2-yl)oxy)benzamido)pyridine 1-Oxide (3rl).

Purified by analytical TLC on silica gel with CH_2Cl_2 /acetone (10:1) as an eluent ($R_f = 0.40$) to afford a white solid (59 mg, 71%, mp 141–142 °C from 1:4 hexane/dichloromethane). ^1H NMR (400 MHz, CDCl_3): δ 10.28 (s, 1H), 8.60 (dd, $J = 8.4, 1.6$ Hz, 1H), 8.27–8.26 (m, 1H), 7.46–7.39 (m, 2H), 7.30–7.28 (m, 1H), 7.10–7.04 (m, 2H), 5.02–4.96 (m, 1H). ^{13}C NMR (100 MHz, CDCl_3): δ 161.8, 154.3, 143.7, 137.3, 132.8, 131.2, 128.1, 127.7, 126.0, 120.6 ($q, J_{\text{C}-\text{F}} = 285.4$ Hz), 119.5, 115.0, 113.7, 76.1 ($p, J_{\text{C}-\text{F}} = 33.7$ Hz). ^{19}F NMR (376 MHz, CDCl_3): δ -73.09. HRMS (positive ESI): calcd for $\text{C}_{15}\text{H}_{10}\text{ClF}_6\text{N}_2\text{O}_3$ [M + H], 415.0284; found, 415.0281.

2-(2-((Hexafluoropropan-2-yl)oxy)-6-nitrobenzamido)pyridine 1-Oxide (3sl).

Purified by analytical TLC on silica gel with CH_2Cl_2 /acetone (6:1) as an eluent ($R_f = 0.35$) to afford a yellow solid (46 mg, 54%, mp 162–163 °C from 1:4 hexane/dichloromethane). ^1H NMR (400 MHz, CDCl_3): δ 10.42 (s, 1H), 8.56 (dd, $J = 8.4, 1.2$ Hz, 1H), 8.24–8.22 (m, 1H), 8.06 (d, $J = 8.2$ Hz, 1H), 7.71–7.67 (m, 1H), 7.50–7.41 (m, 2H), 7.10–7.06 (m, 1H), 5.13–5.08 (m, 1H). ^{13}C NMR (100 MHz, CDCl_3): δ 160.8, 154.2, 146.6, 143.7, 137.2, 131.9, 128.4, 123.7, 121.2, 120.5 ($q, J_{\text{C}-\text{F}} = 282.4$ Hz), 119.5, 115.1,

76.2 ($\text{p}, J_{\text{C}-\text{F}} = 33.7$ Hz). ^{19}F NMR (376 MHz, CDCl_3): δ -72.95. HRMS (positive ESI): calcd for $\text{C}_{15}\text{H}_{10}\text{F}_6\text{N}_3\text{O}_5$ [M + H], 426.0525; found, 426.0524.

2-(2-((Hexafluoropropan-2-yl)oxy)-4,6-dimethylbenzamido)-pyridine 1-Oxide (3tl). Purified by analytical TLC on silica gel with CH_2Cl_2 /acetone (10:1) as an eluent ($R_f = 0.39$) to afford a white solid (74 mg, 91%, mp 105–106 °C from 1:5 hexane/dichloromethane). ^1H NMR (400 MHz, CDCl_3): δ 10.17 (s, 1H), 8.62–8.60 (m, 1H), 8.26–8.25 (m, 1H), 7.40–7.36 (m, 1H), 7.06–7.03 (m, 1H), 6.89 (s, 1H), 6.72 (s, 1H), 4.97–4.91 (m, 1H), 2.37 (s, 6H). ^{13}C NMR (100 MHz, CDCl_3): δ 165.1, 153.7, 144.1, 141.9, 137.9, 137.3, 128.1, 127.5, 125.0, 120.8 (q, $J_{\text{C}-\text{F}} = 285.1$ Hz), 119.0, 114.8, 112.9, 76.0 (p, $J_{\text{C}-\text{F}} = 33.4$ Hz), 21.6, 19.3. ^{19}F NMR (376 MHz, CDCl_3): δ -73.22. HRMS (positive ESI): calcd for $\text{C}_{17}\text{H}_{15}\text{F}_6\text{N}_2\text{O}_3$ [M + H], 409.0987; found, 409.0986.

2-(5-Chloro-2-((hexafluoropropan-2-yl)oxy)benzamido)-pyridine 1-Oxide (3ul). Purified by analytical TLC on silica gel with CH_2Cl_2 /acetone (10:1) as an eluent ($R_f = 0.41$) to afford a white solid (77 mg, 93%, mp 127–128 °C from 1:5 hexane/dichloromethane). ^1H NMR (400 MHz, CDCl_3): δ 11.24 (s, 1H), 8.60 (dd, $J = 8.6, 1.7$ Hz, 1H), 8.31–8.29 (m, 1H), 8.05 (d, $J = 2.7$ Hz, 1H), 7.54 (dd, $J = 8.9, 2.7$ Hz, 1H), 7.40–7.36 (m, 1H), 7.15 (d, $J = 8.9$ Hz, 1H), 7.08–7.04 (m, 1H), 5.15–5.09 (m, 1H). ^{13}C NMR (100 MHz, CDCl_3): δ 161.7, 153.1, 144.2, 137.2, 133.7, 132.1, 130.7, 127.7, 126.3, 120.6 (q, $J_{\text{C}-\text{F}} = 285.3$ Hz), 119.3, 117.0, 115.4, 76.6 (p, $J_{\text{C}-\text{F}} = 33.9$ Hz). ^{19}F NMR (376 MHz, CDCl_3): δ -72.77. HRMS (positive ESI): calcd for $\text{C}_{15}\text{H}_{10}\text{ClF}_6\text{N}_2\text{O}_3$ [M + H], 415.0284; found, 415.0283.

2-(4,5-Dichloro-2-((hexafluoropropan-2-yl)oxy)benzamido)-pyridine 1-Oxide (3vl). Purified by analytical TLC on silica gel with CH_2Cl_2 /acetone (10:1) as an eluent ($R_f = 0.49$) to afford a white solid (75 mg, 84%, mp 137–138 °C from 1:5 hexane/dichloromethane). ^1H NMR (400 MHz, CDCl_3): δ 11.26 (s, 1H), 8.60–8.58 (m, 1H), 8.31–8.29 (m, 1H), 8.20 (s, 1H), 7.40–7.36 (m, 1H), 7.32 (s, 1H), 7.08–7.05 (m, 1H), 5.17–5.12 (m, 1H). ^{13}C NMR (100 MHz, CDCl_3): δ 160.9, 152.9, 144.2, 137.9, 137.3, 133.7, 129.6, 127.7, 124.5, 120.4 (q, $J_{\text{C}-\text{F}} = 282.6$ Hz), 119.4, 117.8, 115.5, 76.7 (p, $J_{\text{C}-\text{F}} = 34.3$ Hz). ^{19}F NMR (376 MHz, CDCl_3): δ -72.64. HRMS (positive ESI): calcd for $\text{C}_{15}\text{H}_9\text{Cl}_2\text{F}_6\text{N}_2\text{O}_3$ [M + H], 448.9894; found, 448.9889.

2-(2-((Hexafluoropropan-2-yl)oxy)-4,5-dimethoxybenzamido)-pyridine 1-Oxide (3wl). Purified by analytical TLC on silica gel with CH_2Cl_2 /acetone (5:1) as an eluent ($R_f = 0.32$) to afford a white solid (71 mg, 80%, mp 170–171 °C from 1:5 hexane/dichloromethane). ^1H NMR (400 MHz, CDCl_3): δ 11.36 (s, 1H), 8.62 (dd, $J = 8.5, 1.6$ Hz, 1H), 8.31–8.29 (m, 1H), 7.58 (s, 1H), 7.37–7.33 (m, 1H), 7.03–7.00 (m, 1H), 6.62 (s, 1H), 5.04–4.99 (m, 1H), 3.97 (s, 3H), 3.95 (s, 3H). ^{13}C NMR (100 MHz, CDCl_3): δ 162.8, 153.5, 149.7, 146.2, 144.7, 137.3, 127.5, 120.7 (q, $J_{\text{C}-\text{F}} = 283.0$ Hz), 118.8, 116.6, 115.2, 113.1, 100.0, 77.7 (p, $J_{\text{C}-\text{F}} = 33.5$ Hz), 56.4, 56.3. ^{19}F NMR (376 MHz, CDCl_3): δ -72.67. HRMS (positive ESI): calcd for $\text{C}_{17}\text{H}_{15}\text{F}_6\text{N}_2\text{O}_5$ [M + H], 441.0885; found, 441.0886.

2-(2-((Hexafluoropropan-2-yl)oxy)-1-naphthamido)pyridine 1-Oxide (3xl). Purified by analytical TLC on silica gel with CH_2Cl_2 /acetone (10:1) as an eluent ($R_f = 0.47$) to afford a white solid (70 mg, 81%, mp 106–107 °C from 1:5 hexane/dichloromethane). ^1H NMR (400 MHz, CDCl_3): δ 10.41 (s, 1H), 8.73–8.71 (m, 1H), 8.25–8.23 (m, 1H), 7.98 (d, $J = 9.2$ Hz, 1H), 7.93 (d, $J = 8.4$ Hz, 1H), 7.87 (d, $J = 8.0$ Hz, 1H), 7.59–7.50 (m, 2H), 7.44–7.40 (m, 1H), 7.30 (d, $J = 9.1$ Hz, 1H), 7.07–7.04 (m, 1H), 5.14–5.08 (m, 1H). ^{13}C NMR (100 MHz, CDCl_3): δ 164.5, 150.8, 144.0, 137.3, 132.9, 130.7, 130.5, 128.7, 128.3, 128.1, 126.4, 124.5, 123.2, 120.8 (q, $J_{\text{C}-\text{F}} = 285.1$ Hz), 119.3, 115.2, 115.0, 76.6 (p, $J_{\text{C}-\text{F}} = 33.4$ Hz). ^{19}F NMR (376 MHz, CDCl_3): δ -73.08. HRMS (positive ESI): calcd for $\text{C}_{19}\text{H}_{13}\text{F}_6\text{N}_2\text{O}_3$ [M + H], 431.0830; found, 431.0826.

2-(3-((Hexafluoropropan-2-yl)oxy)thiophene-2-carboxamido)-pyridine 1-Oxide (3yl). Purified by analytical TLC on silica gel with CH_2Cl_2 /acetone (6:1) as an eluent ($R_f = 0.37$) to afford a white solid (57 mg, 74%, mp 161–162 °C from 1:5 hexane/dichloromethane). ^1H NMR (400 MHz, CDCl_3): δ 11.29 (s, 1H), 8.57 (d, $J = 7.5$ Hz, 1H), 8.31–8.30 (m, 1H), 7.63 (d, $J = 5.6$ Hz, 1H), 7.35–7.31 (m, 1H), 7.04–7.00 (m, 1H), 6.97 (d, $J = 5.6$ Hz, 1H), 5.18–5.13 (m, 1H). ^{13}C

NMR (100 MHz, CDCl_3): δ 158.6, 152.6, 144.5, 137.3, 132.2, 127.7, 120.6, 120.5 (q, $J_{\text{C}-\text{F}} = 280.0$ Hz), 118.9, 115.8, 115.3, 76.8 (p, $J_{\text{C}-\text{F}} = 34.2$ Hz). ^{19}F NMR (376 MHz, CDCl_3): δ -72.81. HRMS (positive ESI): calcd for $\text{C}_{13}\text{H}_9\text{F}_6\text{N}_2\text{O}_3$ [M + H], 387.0238; found, 387.0235.

2-(3-((Hexafluoropropan-2-yl)oxy)furan-2-carboxamido)-pyridine 1-Oxide (3zl). Purified by analytical TLC on silica gel with CH_2Cl_2 /acetone (6:1) as an eluent ($R_f = 0.44$) to afford a white solid (28 mg, 38%, mp 153–154 °C from 1:5 hexane/dichloromethane). ^1H NMR (400 MHz, CDCl_3): δ 10.94 (s, 1H), 8.55 (d, $J = 7.8$ Hz, 1H), 8.31–8.30 (m, 1H), 7.50 (d, $J = 2.0$ Hz, 1H), 7.38–7.34 (m, 1H), 7.06–7.03 (m, 1H), 6.51 (d, $J = 2.0$ Hz, 1H), 6.09–6.03 (m, 1H). ^{13}C NMR (100 MHz, CDCl_3): δ 155.6, 151.0, 144.7, 144.0, 137.3, 131.2, 128.2, 120.8 (q, $J_{\text{C}-\text{F}} = 284.6$ Hz), 119.0, 114.9, 107.2, 76.5 (p, $J_{\text{C}-\text{F}} = 33.6$ Hz). ^{19}F NMR (376 MHz, CDCl_3): δ -73.32. HRMS (positive ESI): calcd for $\text{C}_{13}\text{H}_9\text{F}_6\text{N}_2\text{O}_4$ [M + H], 371.0467; found, 371.0462.

General Procedure for Removal of the Directing Group. A mixture of 2-(2-ethoxybenzamido)pyridine 1-oxide (51.6 mg, 0.2 mmol) and NaOH (120 mg, 3 mmol) in EtOH (2 mL) was stirred at 80 °C for 8 h. After completion of the reaction, the resulting dark red solution was cooled to room temperature and quenched with 2 M HCl aqueous solution (15 mL). The mixture was extracted with CH_2Cl_2 (3 × 15 mL). The organic layers were combined, dried over MgSO_4 , and filtered, and the solvent was evaporated under a vacuum. Purification by silica gel column chromatography (CH_2Cl_2 /methanol, 20:1) afforded 2-ethoxybenzoic acid 10 as a light yellow oil (27 mg, 80%, CAS: 134-11-2). ^1H NMR (400 MHz, CDCl_3): δ 10.97 (bs, 1H), 8.18 (dd, $J = 7.8, 1.8$ Hz, 1H), 7.58–7.54 (m, 1H), 7.15–7.11 (m, 1H), 7.05 (d, $J = 8.3$ Hz, 1H), 4.34 (q, $J = 7.0$ Hz, 2H), 1.57 (t, $J = 7.0$ Hz, 3H). ^{13}C NMR (100 MHz, CDCl_3): δ 165.6, 157.4, 135.1, 133.7, 122.2, 117.7, 112.6, 66.0, 14.7.

ASSOCIATED CONTENT

S Supporting Information

^1H and ^{13}C NMR spectra for all new compounds. This material is available free of charge via the Internet at <http://pubs.acs.org>.

AUTHOR INFORMATION

Corresponding Authors

*E-mail: niujunlong@zzu.edu.cn.

*E-mail: mpsong@zzu.edu.cn.

Notes

The authors declare no competing financial interest.

ACKNOWLEDGMENTS

We are grateful to the National Natural Science Foundation of China (Grants 21072177 and 21272217) for financial support of this work.

REFERENCES

- (1) For recent reviews, see: (a) Alberico, D.; Scott, M. E.; Lautens, M. *Chem. Rev.* **2007**, *107*, 174. (b) Gevorgyan, V. *Chem. Soc. Rev.* **2007**, *36*, 1173. (c) Park, Y. J.; Park, J.-W.; Jun, C.-H. *Acc. Chem. Res.* **2008**, *41*, 222. (d) Lewis, L. C.; Bergman, R. G.; Ellman, J. A. *Acc. Chem. Res.* **2008**, *41*, 1013. (e) Yeung, C. S.; Dong, V. M. *Chem. Rev.* **2011**, *111*, 1215. (f) Baudoin, O. *Chem. Soc. Rev.* **2011**, *40*, 4902. (g) Kuhl, N.; Hopkinson, M. N.; Wencel-Delord, J.; Glorius, F. *Angew. Chem., Int. Ed.* **2012**, *51*, 10236. (h) Bellina, F.; Rossi, R. *Chem. Rev.* **2010**, *110*, 1082. (i) Wendlandt, A. E.; Suess, A. M.; Stahl, S. S. *Angew. Chem., Int. Ed.* **2011**, *50*, 11062. (j) Cho, S. H.; Kim, J. Y.; Kwak, J.; Chang, S. *Chem. Soc. Rev.* **2011**, *40*, 5068. (k) Bras, J. L.; Muzart, J. *Chem. Rev.* **2011**, *111*, 1170. (l) Yamaguchi, J.; Yamaguchi, A. D.; Itami, K. *Angew. Chem., Int. Ed.* **2012**, *51*, 8960. (m) Liu, C.; Zhang, H.; Shi, W.; Lei, A. *Chem. Rev.* **2011**, *111*, 1780. (n) Li, B.-J.; Shi, Z.-J. *Chem. Soc. Rev.* **2012**, *41*, 5588.
- (2) For recent reviews, see: (a) Beccalli, E. M.; Broggini, G.; Martinelli, M.; Sottocornola, S. *Chem. Rev.* **2007**, *107*, 5318. (b) Colby,

- D. A.; Bergman, R. G.; Ellman, J. A. *Chem. Rev.* **2010**, *110*, 624.
 (c) McGlacken, G. P.; Bateman, L. M. *Chem. Soc. Rev.* **2009**, *38*, 2447.
 (3) For selected references, see: (a) John, A.; Nicholas, K. M. *J. Org. Chem.* **2011**, *76*, 4158. (b) Pan, J.; Su, M.; Buchwald, S. L. *Angew. Chem., Int. Ed.* **2011**, *50*, 8647. (c) Wang, H.; Yu, Y.; Hong, X.; Tan, Q.; Xu, B. *J. Org. Chem.* **2014**, *79*, 3279. (d) Xu, H.; Qiao, X.; Yang, S.; Shen, Z. *J. Org. Chem.* **2014**, *79*, 4414.
 (4) For selected references, see: (a) Chen, X.; Hao, X.-S.; Goodhue, C. E.; Yu, J.-Q. *J. Am. Chem. Soc.* **2006**, *128*, 6790. (b) Xiao, B.; Gong, T.-J.; Liu, Z.-J.; Liu, J.-H.; Luo, D.-F.; Xu, J.; Liu, L. *J. Am. Chem. Soc.* **2011**, *133*, 9250. (c) Wei, Y.; Yoshikai, N. *Org. Lett.* **2011**, *13*, 5504. (d) Zhao, J.; Wang, Y.; He, Y.; Liu, L.; Zhu, Q. *Org. Lett.* **2012**, *14*, 1078. (e) Zhang, C.; Feng, P.; Jiao, N. *J. Am. Chem. Soc.* **2013**, *135*, 15257. (f) Takemura, N.; Kuninobu, Y.; Kanai, M. *Org. Lett.* **2013**, *15*, 844. (g) Shan, G.; Yang, X.; Zong, Y.; Rao, Y. *Angew. Chem., Int. Ed.* **2013**, *52*, 13606.
 (5) For some recent reviews, see: (a) Musaev, D. G.; Figg, T. M.; Kaledin, A. L. *Chem. Soc. Rev.* **2014**, *43*, 5009. (b) Wu, Y.; Wang, J.; Mao, F.; Kwong, F. Y. *Chem.—Asian J.* **2014**, *9*, 26. (c) Franzoni, I.; Mazet, C. *Org. Biomol. Chem.* **2014**, *12*, 233.
 (6) (a) Song, G.; Wang, F.; Li, X. *Chem. Soc. Rev.* **2012**, *41*, 3651. (b) Jayakumar, J.; Parthasarathy, K.; Chen, Y.-H.; Lee, T.-H.; Chuang, S.-C.; Cheng, C.-H. *Angew. Chem., Int. Ed.* **2014**, *53*, 9889 and references therein.
 (7) For recent reviews, see: (a) Ackermann, L. *Chem. Rev.* **2011**, *111*, 1315. (b) Ackermann, L. *Acc. Chem. Res.* **2014**, *47*, 281. (c) Arockiam, P. B.; Bruneau, C.; Dixneuf, P. H. *Chem. Rev.* **2012**, *112*, 5879.
 (8) (a) Kitahara, M.; Umeda, N.; Hirano, K.; Satoh, T.; Miura, M. *J. Am. Chem. Soc.* **2011**, *133*, 2160. (b) Nishino, M.; Hirano, K.; Satoh, T.; Miura, M. *Angew. Chem., Int. Ed.* **2013**, *52*, 4457. (c) Odani, R.; Hirano, K.; Satoh, T.; Miura, M. *J. Org. Chem.* **2013**, *78*, 11045.
 (9) For related studies, see: (a) Mao, Z.; Wang, Z.; Xu, Z.; Huang, F.; Yu, Z.; Wang, R. *Org. Lett.* **2012**, *14*, 3854. (b) Fan, S.; Chen, Z.; Zhang, X. *Org. Lett.* **2012**, *14*, 4950. (c) Qin, X.; Feng, B.; Dong, J.; Li, X.; Xue, Y.; Lan, J.; You, J. *J. Org. Chem.* **2012**, *77*, 7677.
 (10) Enthalier, S.; Company, A. *Chem. Soc. Rev.* **2011**, *40*, 4912.
 (11) (a) Altman, R. A.; Shafir, A.; Lichtor, P. A.; Buchwald, S. L. *J. Org. Chem.* **2008**, *73*, 284. (b) Hartwig, J. F. *Nature* **2008**, *455*, 314.
 (12) For a review of Ullmann-type coupling reactions, see: Monnier, F.; Taillefer, M. *Angew. Chem., Int. Ed.* **2009**, *48*, 6954.
 (13) For a review, see: Qiao, J. X.; Lam, P. Y. S. *Synthesis* **2011**, 829.
 (14) For a book, see: Li, J. *J. Name Reactions*; Springer: New York, 2014; p 628.
 (15) For a review, see: Kumara Swamy, K. C.; Bhuvan Kumar, N. N.; Balaraman, E.; Pavan Kumar, K. V. P. *Chem. Rev.* **2009**, *109*, 2551.
 (16) (a) Zou, Y.-Q.; Chen, J.-R.; Liu, X.-P.; Lu, L.-Q.; Davis, R. L.; Jørgensen, K. A.; Xiao, W.-J. *Angew. Chem., Int. Ed.* **2012**, *51*, 784. (b) Yan, Y.; Feng, P.; Zheng, Q.-Z.; Liang, Y.-F.; Lu, J.-F.; Cui, Y.; Jiao, N. *Angew. Chem., Int. Ed.* **2013**, *52*, 5827. (c) Zhang, Y.-H.; Yu, J.-Q. *J. Am. Chem. Soc.* **2009**, *131*, 14654. (d) Shan, G.; Yang, X.; Ma, L.; Rao, Y. *Angew. Chem., Int. Ed.* **2012**, *51*, 13070. (e) Mo, F.; Trzepkowski, L. J.; Dong, G. *Angew. Chem., Int. Ed.* **2012**, *51*, 13075.
 (17) (a) Emmert, M. H.; Cook, A. K.; Xie, Y. J.; Sanford, M. S. *Angew. Chem., Int. Ed.* **2011**, *50*, 9409. (b) Cheng, X.-F.; Li, Y.; Su, Y.-M.; Yin, F.; Wang, J.-Y.; Sheng, J.; Vora, H. U.; Wang, X.-S.; Yu, J.-Q. *J. Am. Chem. Soc.* **2013**, *135*, 1236. (c) Wang, W.; Luo, F.; Zhang, S.; Cheng, J. *J. Org. Chem.* **2010**, *75*, 2415.
 (18) (a) Hoover, J. M.; Ryland, B. L.; Stahl, S. S. *J. Am. Chem. Soc.* **2013**, *135*, 2357. (b) Kumpulainen, E. T. T.; Koskinen, A. M. P. *Chem.—Eur. J.* **2009**, *15*, 10901. (c) Okada, T.; Awasa, T.; Sugiyama, Y.; Kirihara, M.; Iwai, T.; Kimura, Y. *Synlett* **2014**, *25*, 596.
 (19) (a) Wang, X.; Lu, Y.; Dai, H.-X.; Yu, J.-Q. *J. Am. Chem. Soc.* **2010**, *132*, 12203. (b) Jiang, T.-S.; Wang, G.-W. *J. Org. Chem.* **2012**, *77*, 9504. (c) Dick, A. R.; Hull, K. L.; Sanford, M. S. *J. Am. Chem. Soc.* **2004**, *126*, 2300. (d) Li, W.; Sun, P. *J. Org. Chem.* **2012**, *77*, 8362. (e) Desai, L. V.; Malik, H. A.; Sanford, M. S. *Org. Lett.* **2006**, *8*, 1141. (f) Wang, G.-W.; Yuan, T.-T. *J. Org. Chem.* **2010**, *75*, 476. (g) Wang, H.; Li, G.; Engle, K. M.; Yu, J.-Q.; Davies, H. M. L. *J. Am. Chem. Soc.* **2013**, *135*, 6774. (h) Shi, S.; Kuang, C. *J. Org. Chem.* **2014**, *79*, 6105.

- (i) Chen, F.-J.; Zhao, S.; Hu, F.; Chen, K.; Zhang, Q.; Zhang, S.-Q.; Shi, B.-F. *Chem. Sci.* **2013**, *4*, 4187. (j) Gao, T.; Sun, P. *J. Org. Chem.* **2014**, *79*, 9888.
 (20) (a) Bhadra, S.; Dzik, W. I.; Goofßen, L. *J. Angew. Chem., Int. Ed.* **2013**, *52*, 2959. (b) Bhadra, S.; Mattheis, C.; Katayev, D.; Goofßen, L. *J. Angew. Chem., Int. Ed.* **2013**, *52*, 9279.
 (21) (a) Huffman, L. M.; Casitas, A.; Font, M.; Canta, M.; Costas, M.; Ribas, X.; Stahl, S. S. *Chem.—Eur. J.* **2011**, *17*, 10643. (b) King, A. E.; Huffman, L. M.; Casitas, A.; Costas, M.; Ribas, X.; Stahl, S. S. *J. Am. Chem. Soc.* **2010**, *132*, 12068. (c) Suess, A. M.; Ertem, M. Z.; Cramer, C. J.; Stahl, S. S. *J. Am. Chem. Soc.* **2013**, *135*, 9797.
 (22) Zaitsev, V. G.; Shabashov, D.; Daugulis, O. *J. Am. Chem. Soc.* **2005**, *127*, 13154.
 (23) (a) Truong, T.; Klimovica, K.; Daugulis, O. *J. Am. Chem. Soc.* **2013**, *135*, 9342. (b) Tran, L. D.; Roane, J.; Daugulis, O. *Angew. Chem., Int. Ed.* **2013**, *52*, 6043. (c) Tran, L. D.; Popov, I.; Daugulis, O. *J. Am. Chem. Soc.* **2012**, *134*, 18237. (d) Roane, J.; Daugulis, O. *Org. Lett.* **2013**, *15*, 5842. (e) Grigorjeva, L.; Daugulis, O. *Angew. Chem., Int. Ed.* **2014**, *53*, 10209.
 (24) Shang, R.; Ilies, L.; Matsumoto, A.; Nakamura, E. *J. Am. Chem. Soc.* **2013**, *135*, 6030.
 (25) (a) Inoue, S.; Shiota, H.; Fukumoto, Y.; Chatani, N. *J. Am. Chem. Soc.* **2009**, *131*, 6898. (b) Aihara, Y.; Chatani, N. *Chem. Sci.* **2013**, *4*, 664. (c) Aihara, Y.; Chatani, N. *J. Am. Chem. Soc.* **2013**, *135*, 5308.
 (26) (a) He, G.; Chen, G. *Angew. Chem., Int. Ed.* **2011**, *50*, 5192. (b) Zhang, S.-Y.; He, G.; Zhao, Y.; Wright, K.; Nack, W. A.; Chen, G. *J. Am. Chem. Soc.* **2012**, *134*, 7313. (c) Zhang, S.-Y.; He, G.; Nack, W. A.; Zhao, Y.; Li, Q.; Chen, G. *J. Am. Chem. Soc.* **2013**, *135*, 2124. (d) Li, Q.; Zhang, S.-Y.; He, G.; Ai, Z.; Nack, W. A.; Chen, G. *Org. Lett.* **2014**, *16*, 1764.
 (27) (a) Li, X.; Liu, Y.-H.; Gu, W.-J.; Li, B.; Chen, F.-J.; Shi, B.-F. *Org. Lett.* **2014**, *16*, 3904. (b) Dong, J.; Wang, F.; You, J. *Org. Lett.* **2014**, *16*, 2884. (c) Wu, X.; Zhao, Y.; Zhang, G.; Ge, H. *Angew. Chem., Int. Ed.* **2014**, *53*, 3706. (d) Sun, W.-W.; Cao, P.; Mei, R.-Q.; Li, Y.; Ma, Y.-L.; Wu, B. *Org. Lett.* **2014**, *16*, 480. (e) Zhang, L.-S.; Chen, G.; Wang, X.; Guo, Q.-Y.; Zhang, X.-S.; Pan, F.; Chen, K.; Shi, Z.-J. *Angew. Chem., Int. Ed.* **2014**, *53*, 3899. (f) Rit, R. K.; Yadav, M. R.; Sahoo, A. K. *Org. Lett.* **2012**, *14*, 3724. (g) Rodríguez, N.; Romero-Revilla, J. A.; Fernández-Ibáñez, M. Á.; Carretero, J. C. *Chem. Sci.* **2013**, *4*, 175. (h) Ye, X.; He, Z.; Ahmed, T.; Weise, K.; Akhmedov, N. G.; Petersen, J. L.; Shi, X. *Chem. Sci.* **2013**, *4*, 3712. (i) Gu, Q.; Al Mamari, H. H.; Graczyk, K.; Diers, E.; Ackermann, L. *Angew. Chem., Int. Ed.* **2014**, *53*, 3868. (j) Huang, L.; Sun, X.; Li, Q.; Qi, C. *J. Org. Chem.* **2014**, *79*, 6720.
 (28) For a recent review of direct C—H functionalization aided by a bidentate directing group, see: Rouquet, G.; Chatani, N. *Angew. Chem., Int. Ed.* **2013**, *52*, 11726.
 (29) Hao, X.-Q.; Chen, L.-J.; Ren, B.; Li, L.-Y.; Yang, X.-Y.; Gong, J.-F.; Niu, J.-L.; Song, M.-P. *Org. Lett.* **2014**, *16*, 1104.
 (30) (a) Hoover, J. M.; Stahl, S. S. *J. Am. Chem. Soc.* **2011**, *133*, 16901. (b) Gamez, P.; Reedijk, I. W. C. E. J.; Sheldon, R. A. *Chem. Commun.* **2003**, 2414.
 (31) (a) Sun, R.; Liu, Y.; Zhang, Y.; Xiong, Li.; Wang, Q. *J. Agric. Food Chem.* **2011**, *59*, 2471. (b) Xu, X. Y.; Qian, X. H.; Li, Z.; Huang, Q. *C. J. Fluorine Chem.* **2003**, *121*, 51.
 (32) Mirica, L. M.; Ottenwaelder, X.; Stack, D. P. *Chem. Rev.* **2004**, *104*, 1013.
 (33) (a) Chen, P.; Root, D. E.; Campochiaro, C.; Fujisawa, K.; Solomon, E. I. *J. Am. Chem. Soc.* **2003**, *125*, 466. (b) Klinman, J. P. *Chem. Rev.* **1996**, *96*, 2541. (c) Whittaker, J. W. *Chem. Rev.* **2003**, *103*, 2347.